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Abstract
Schizophrenia is a devastating neurological disorder that affects approximately 1% of the
population and is characterized by positive, negative, and/or cognitive symptoms. 
Positive symptoms are associated with increased glutamate (Glu) and/or dopamine (DA)
signaling in the nucleus accumbens (NAcc) while negative and cognitive symptoms are
related to decreased Glu and/or DA signaling in the medial prefrontal cortex (mPFC) and
hippocampus.   The etiology of the disorder remains unknown, yet it is believed to be the
result of a combination of genetic and neurodevelopmental factors.  In order to improve
our understanding of schizophrenia it is important to develop and further characterize
animal models with relevance to the human condition.
Prior research has demonstrated that rodents exposed to neonatal treatment with domoic
acid (DOM) (20 ìg/kg), a kainate (KA) receptor (KAR) agonist, during a critical period
of brain development (i.e. post-natal day (PND) 8-14) produces animals that exhibit
several behavioural, neurochemical, and neuroanatomical abnormalities that are
characteristic of schizophrenia.  
The purpose of this thesis is to further examine the potential of DOM treatment in
producing an animal model of schizophrenia by assessing cognitive functioning (i.e. face
validity) using the attentional set-shifting and puzzle box paradigms, employing
immunohistochemistry to examine dopamine transporter (DAT), D1 receptor, and D2
receptor as markers of the DA system in the mPFC (i.e. construct validity), and by
vassessing active caspase-3, an executioner caspase in cellular apoptosis, in the mPFC (i.e.
etiological validity).
Behavioural results indicate improved cognitive flexibility among DOM-treated males in
the attentional set-shifting paradigm and improved short-term memory and problem
solving ability among DOM-treated females in the puzzle box.  Neurochemical results
indicate increased DAT staining in the right PRL of DOM-treated females, decreased
caspase-3 staining, as evidenced by optical density measurement, in the right PRL among
DOM-treated males, and decreased caspase-3 staining, as evidenced by cell count
measurement, in the right PRL among DOM-treated females.  These results serve to
strengthen the face validity, construct validity, and etiological validity of the model as
they demonstrate cognitive alterations, neurochemical alterations in adulthood which are
associated with behavioural symptomatology, and neurochemical alterations during
development.
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1Chapter 1
General Introduction
21.1 Schizophrenia
Schizophrenia is a debilitating psychiatric disorder that afflicts approximately 1% of the
population (Goeree et al., 2005) and is associated with significant emotional and
economic impact for patients, families, and society as a whole.  For example, issues
related to health-care costs and unemployment in patients with schizophrenia have been
shown to cost the Canadian government approximately $6.85 billion annually (Goeree et
al., 2005).  While schizophrenia is certainly a prevalent and significant disorder, it was
only identified relatively recently by Emil Kraepelin and Eugen Bleuler (as reviewed in
Brockington and Leff, 1979; as reviewed in Tamminga and Holcomb, 2005). 
Schizophrenia was originally identified by Emil Kraepelin when it was referred to as
“dementia praecox”, meaning premature dementia (as reviewed in Brockington and Leff,
1979), before being subsequently classified as schizophrenia by Eugen Bleuler in 1911
(as reviewed in Tamminga and Holcomb, 2005).  
The symptomatology of schizophrenia is extremely diverse and is characterized by (i)
positive symptoms; marked by the presence of abnormal behaviours (e.g. delusions), (ii)
negative symptoms; marked by absence of normal behaviours (e.g. social withdrawal) or
(iii) cognitive symptoms; marked mainly by learning and/or memory deficits (e.g.
working memory dysfunction) (DSM-IV-TR, 2000).  The core diagnosis of schizophrenia
requires various criteria to be met, including (i) the presence of two of the following:
delusions, hallucinations, disorganized speech, disorganized behaviour, negative
symptoms, (ii) social or occupational dysfunction, (iii) symptom duration of at least six
3months, (iv) the absence of a diagnosis of schizoaffective disorder or a mood disorder,
and (v) the absence of substance abuse or a general medical condition which would
explain behavioural findings (DSM-IV-TR, 2000).  Based on the constellation of
symptoms that are manifested, schizophrenia can then be sub-categorized into various
subtypes including residual, disorganized, catatonic, paranoid, and undifferentiated
schizophrenia  (DSM-IV-TR, 2000).  Each subtype of schizophrenia has certain features,
in addition to core features of schizophrenia, which predominate.  For example, the
diagnosis of disorganized schizophrenia requires the presence of both disorganized
behaviour and flattened affect (DSM-IV-TR, 2000).  Also, slow and abnormal
movements typify catatonic schizophrenia, while preoccupation with delusions or
hallucinations characterize paranoid schizophrenia (DSM-IV-TR, 2000).  Residual
schizophrenia can be considered a somewhat less severe version of paranoid
schizophrenia and, finally, undifferentiated schizophrenia is typified by symptoms of
schizophrenia which do not meet the criteria of any of the other subtypes (DSM-IV-TR,
2000).
The heterogeneity of schizophrenia, as seen through the various behavioural
manifestations and subcategories, is further demonstrated in terms of developmental time
course and gender differences.  In terms of developmental time course, while patients are
typically diagnosed with schizophrenia at some point between the late teenage years or
early adulthood, the diagnosis has also been seen to occur in children and in the elderly
(Rabins et al., 1984).  Additionally, patients often exhibit a prodromal period prior to
4diagnosis where, while the diagnostic criteria for schizophrenia are not met, behaviour is
often described as atypical and may include introversion, peculiar interests,
suspiciousness, or sudden changes in personality (Gourzis et al., 2002).  The prodromal
period has also been shown to include deficits in both academic and social functioning in
individuals who are subsequently diagnosed with schizophrenia (Allen et al., 2005). 
Gender differences also seem to exist during the prodromal period, with males more
frequently exhibiting negative and cognitive symptoms (Choi et al., 2009).  While there is
inherent variability between patients in terms of disease progression, following the
prodromal period, there is a standard progression of schizophrenia which involves
negative symptoms emerging first, often during the late teenage years or during the early
twenties, cognitive symptoms following shortly after, and positive symptoms generally
not appearing until years later (DeLisi, 1992).  Gender difference also exist during the
clinical period, as men exhibit an earlier onset and more pronounced negative and
cognitive symptoms (Goldstein and Lewine, 2000). 
The existence of an early prodromal period points to a neurodevelopmental etiology of
the disorder, which is further supported by epidemiological studies demonstrating that
various prenatal and perinatal factors are associated with the subsequent development of
schizophrenia.  These factors include prenatal exposure to influenza (Mednick et al.,
1994), other types of maternal infection (Brown, 2006), maternal stress (Malaspina et al.,
2008), and prenatal exposure to toxins (Opley et al., 2008).  Notably, these factors are all
associated with alterations in glutamate (Glu) tone, a primary neurotransmitter system
5that is implicated in schizophrenia (Parsons et al., 1998; Deutsch et al., 2001; Dracheva et
al., 2001; Gluck et al., 2002) which is also capable of altering dopamine (DA)
functioning, another of the key neurotransmitter systems implicated in schizophrenia, by
modulating DA release (Kretschmer, 1999).
Evidence of the genetic contribution to schizophrenia comes from various sources
including adoption studies (Kety et al., 1994) and twin studies (Gottesman and Shields,
1982; Tsuang et al., 1991).  In fact, the concordance rate in dizygotic twins has been
shown to be 10-15% in dizygotic twins and roughly 50% in monozygotic twins (Onstad et
al., 1991).  Also, several potential susceptibility genes for schizophrenia have been
recently identified and include genes for dysbindin, neuregulin 1, disrupted in
schizophrenia 1 (DISC-1), catechol-O-methyltransferase (COMT), and D-amino-acid
oxidase (as reviewed in Owen et al., 2005).
As can be seen from the variability in developmental time course, gender characteristics,
subtypes, and genetic contributions, schizophrenia is a complex neurodevelopmental
disorder that results from an interaction of environmental and genetic factors.  However,
the etiology of schizophrenia remains unclear.  In order to increase our understanding of
the etiology of schizophrenia and to improve upon the current treatment regimes, it is
necessary to develop novel animal models of the disorder that more closely resemble the
human condition.  
61.1.1 Behavioural alterations
Schizophrenia is a debilitating neurological disorder that is characterized by (i) positive
symptoms; marked by the presence of abnormal behaviours (e.g. delusions and
hallucinations), (ii)  negative symptoms; marked by absence of normal behaviours (e.g.
social withdrawal, avolition) or (iii) cognitive symptoms; marked mainly by learning
and/or memory deficits (e.g. temporal memory dysfunction) (DSM-IV-TR, 2000). 
1.1.1.1 Positive symptoms
Positive symptoms of schizophrenia refer to the presence of abnormal behaviours such as
hallucinations, delusions, disordered thought, and psychomotor agitation, and are
believed to be due in part to DA hyperactivity in the mesolimbic pathway (Stone et al.,
2007). Hallucinations involve perception of stimuli which, in fact, are not present, and
can involve any of the sensory modalities, although auditory hallucinations are most
common.  Not surprisingly, the interpretation of the patient with respect to the source of
these voices, as well as the content of the hallucinations, varies substantially between
patients.  Delusions, which are defined as persistent, obviously false beliefs, are another
common positive symptom of schizophrenia.  The most common forms of delusion
involve delusions of grandeur, which often involve an inflated sense of self-importance,
delusions of persecution where one often feels as though they are being conspired against,
and delusions of reference where random, meaningless events are given some greater
personal meaning (Kimhy et al., 2005).  Disordered thought is perhaps the most common
positive symptom and is typified by irrational thought that does not involve delusions or
7hallucinations (Kerns and Berenbaum, 2002).  The manifestations of hallucinations,
delusions, and disordered thought appear quite similar and have thus been hypothesized
to be the result of a common underlying pathology in the ability to filter out irrelevant
information (Braff et al., 1977; Adler et al., 1982; Light and Braff, 2000).  Finally, a
lesser known and perhaps more discrete positive symptom is psychomotor agitation,
where hyperactivity and/or stereotyped movements are seen.  While the general public
tends to associate positive symptoms most strongly with schizophrenia, it is in fact the
negative and cognitive symptoms which generally emerge first and have a more
significant impact on daily functioning (Rabinowitz et al., 2012).
1.1.1.2 Negative symptoms
Negative symptoms of schizophrenia refer to the absence of normal behaviours and
include blunted affect, anhedonia, alogia, and social withdrawal (DSM-IV-TR, 2000). 
The neurobiological basis of negative symptomatology is believed to be due, in part, to
DA hypoactivity in the mesocortical pathway (Stone et al., 2007).  Blunted affect, or
flattened affect in a more severe form, involves an apparent lack of facial emotion on the
part of a patient and may or may not be associated with anhedonia, which involves a
subjective lack of emotion (DSM-IV-TR, 2000).  Alogia involves poverty in speech or
thought and is often manifested as short, meaningless responses to questioning (DSM-IV-
TR, 2000).  Avolition involves a lack of motivation to participate in normal daily
activities and is closely related to social withdrawal (DSM-IV-TR, 2000).  Blunted affect,
alogia, and avolition may all culminate in social withdrawal, the most common negative
8symptom of schizophrenia, which manifests as either an inability or disinterest in
maintaining social relationships (DSM-IV-TR, 2000).
1.1.1.3 Cognitive symptoms
Although many of the positive (e.g. delusions, hallucinations, and disordered thought)
and negative symptoms (e.g. alogia) bear resemblance to cognitive symptoms, the
cognitive group of symptoms are more restricted to attentional deficits, learning and
memory impairments, and abnormalities in executive functioning (Gold and Harvey,
1993).  Specific findings include impairments in processing speed (Schatz, 1998),
reasoning (Corcoran, 2003), working memory (Conklin et al., 2000), temporal memory
(Schwartz et al., 1991), vigilance (Mar et al., 1996), and social cognition (Hall et al.,
2004).  However, the inter-related aspects of the positive, negative, and cognitive
categories of symptoms relates in part to similarities in the underlying neurobiological
abnormalities that are responsible for the behavioural manifestations of schizophrenia (as
reviewed in Fallon et al., 2003).  The significance of neurocognitive symptoms in
schizophrenia is supported by the findings that cognitive impairments are present, to
some degree, in almost all patients (Green et al., 2004), and that the cognitive symptom
category is most strongly correlated with functional ability (Green, 1996). 
1.1.2  Neuroanatomical alterations
The significant heterogeneity of schizophrenia in terms of potential contributing
etiological agents and symptom categorization is reflected in the diversity of associated
9neuroanatomical and neurochemical abnormalities in the clinical population.  These
include both gross structural abnormalities such as increased lateral ventricular size and
decreased cortical volume (DeLisi et al., 1991), cortical surface abnormalities
(Crespo-Facorro et al., 2000), and fine structural abnormalities of the basal ganglia
(Heckers et al., 1991), thalamus (Pakkenberg, 1992), corpus callosum (Bachmann et al.,
2003), prefrontal cortex (PFC) (Breier et al., 1992), and hippocampus (Takahashi et al.,
2000), to name just a few structures.  Of these areas, two of the prime research targets are
the PFC and the hippocampus.  This is likely due to the clear connection between these
areas and the negative and cognitive symptoms of schizophrenia which, while not being
considered by the general public to be the symptoms most associated with schizophrenia,
have been shown to have the strongest effect on daily functioning and are thought to be
linked to core changes in the ability to filter and process information (Rabinowitz et al.,
2012).
 
1.1.2.1  Hippocampus
The hippocampus is a limbic structure, located in the medial temporal lobe, which
consists of the dentate gyrus and the hippocampus proper, which is sub-divided into
cornu ammonis (CA) 1, CA2, and CA3 (El Falougy and Benuska, 2006).  The CA1, CA2
and CA3 form a well-defined feed-forward Glu pathway known as the trisynaptic circuit
(El Falougy and Benuska, 2006).  First, the perforant pathway projects from the
entorhinal cortex to the molecular layer of the dentate gyrus, which then projects to
pyramidal cells of the stratum radiatum of CA3 via mossy fibers (El Falougy and
10
Benuska, 2006).  Finally, pyramidal cells of CA3 project to pyramidal cells of CA1 via
Schaffer collaterals (El Falougy and Benuska, 2006).  The trisynaptic circuit plays a role
in induction of long-term potentiation, which is believed to be a cellular mechanism for
learning and memory, one of the key functions of the hippocampus (Teyler and Discenna,
1984; Matynia et al., 2002).  The hippocampus also has a role in various pathologies,
including Alzheimer’s disease (Phillips et al., 1991; Du et al., 2001), temporal lobe
epilepsy (McDonald et al., 1991; Cendes et al., 1993), and schizophrenia (as reviewed in
Harrison, 2004).  In terms of schizophrenia, various structural and neurochemical
hippocampal abnormalities have been identified in the clinical population, including
decreased cell counts and cellular disorganization (Jönsson et al., 1999), reduced overall
volume (Narr er al., 2005), and elevated levels of brain-derived neurotrophic factor
(BDNF) and type 2 neurotrophic tyrosine kinase (TrkB) receptor expression (Takahashi et
al., 2000).
1.1.2.2  Prefrontal cortex
The PFC is defined as the cortical areas which receive input from the mediodorsal
nucleus of the thalamus, and can be divided into the lateral PFC, the orbital PFC, and the
medial PFC (mPFC) (Fuster, 2001).  The PFC is specialized to aid in the control of affect,
emotion, social behaviour, and executive function (Fuster, 2001).  The diverse
behavioural roles of the PFC have led to its implication in various conditions such as
attention deficit hyperactivity disorder (Castellanos and Tannock, 2002; Durston et al.,
2006), mood disorders (Drevets et al., 1998; Uranova et al., 2004), and schizophrenia.  In
11
terms of schizophrenia, various prefrontal abnormalities have been identified in the
clinical population, including reduced gray matter volumes (Thompson et al., 2001),
altered TrkB receptors (Takahashi et al., 2000), altered tyrosine hydroxylase levels (Akil
et al., 1999), and reductions in mean neuronal size in layer III (Rajkowska et al., 1998).
1.1.3  Neurochemical alterations
The neurochemistry of schizophrenia parallels the behaviour manifestations of the
disorder in terms of complexity and heterogeneity as several neurotransmitter systems
have been implicated in the pathogenesis and pathophysiology of schizophrenia.  Such
systems include the serotonin system (Joyce et al., 1994; Roth et al., 2004), the
acetylcholine system (Mukherjee et al., 1994; Borda et al., 2002), the ã-aminobutyric acid
(GABA) system (Beasley et al., 2002; Hashimoto et al., 2003), the DA system (Laruelle
et al., 1996; Lindströma et al., 1999), and the Glu system (Dracheva et al., 2001; Gluck et
al., 2002; Bauer et al., 2008).  While the DA system received much of the early attention
with respect to research, the Glu system has been the source of significant research
recently and attempts have been made to merge the DA and Glu hypotheses of
schizophrenia into a single, coherent model (Seeman, 2009).
1.1.3.1  Glutamate
Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous
system (CNS) (Ozawa et al., 1998).  Proper levels of Glu signaling in the developing
brain are critical as Glu has been shown to play an important role in regulating neuronal
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survival, differentiation, and synaptogenesis (McDonald et al., 1990).  Additionally,
abnormal Glu transmission is related to variety of neuropsychiatric diseases, including
schizophrenia (Parsons et al., 1998; Deutsch et al., 2001).
1.1.3.1.1  Biosynthesis of glutamate
While Glu can be synthesized via several biosynthetic pathways, transamination and the
glutamine cycle predominate in the production of Glu (as reviewed in Feldman, 1997). 
Transamination involves transaminase catalysis of á-ketoglutarate, a constituent of the
citric acid cycle, with an á-amino acid to produce both an á-keto acid and Glu (Platt,
2007).  The glutamine cycle is catalyzed by glutaminase and involves the conversion of
glutamine and water to Glu and ammonia (Platt, 2007).  However, transamination differs
from the glutamine cycle in that the original driving force behind the former pathway is
glucose, while Glu itself drives the latter pathway through the conversion of Glu to
glutamine via glutamine synthase.  Thus, there is no net production in the glutamine
cycle, since Glu serves as both the original reactant and the final product.  However, it
has been found that there is differential expression of glutamine synthase, which is
predominantly expressed in astrocytes, and glutaminase, which is predominantly
expressed in neurons, thereby favouring the net production of Glu in neurons (as
reviewed in Feldman, 1997).  Following Glu synthesis by transamination or the glutamine
cycle, Glu is released by presynaptic neurons and diffuses across synapses to exert an
effect on postsynaptic Glu receptors.
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1.1.3.1.2  Glutamate receptor system
The large variety in Glu receptors can be broadly divided in either ionotropic Glu
receptors (iGluRs) or metabotropic Glu receptors (mGluRs) (Ozawa et al., 1998). 
Ionotropic Glu receptors can be further categorized as either á-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) receptors (AMPARs), kainate receptors
(KARs), and N-methyl-D-aspartic acid (NMDA) receptors (NMDARs) (Ozawa et al.,
1998).  When activated by ligand binding, iGluRs serve as cation-specific channels,
thereby allowing the influx of sodium, the efflux of potassium, and, in certain cases, the
influx of calcium, with a net excitatory effect due to electrochemical gradients favouring
sodium influx to potassium efflux (Platt, 2007).  However, AMPARs that contain a
GluR2 subunit that has not undergone post-transcriptional RNA glutamine-to-arginine
editing, KARs that contain either GluR5 or GluR6 subunits that have not undergone post-
transcriptional RNA glutamine-to-arginine editing, and NMDARs can also allow the
influx of calcium ions, a finding that has significance based on the various intracellular
effects of calcium (as reviewed in Vissel et al., 2001).  Increased intracellular calcium
levels can lead to the activation of proteins including protein kinase C, which can in turn
stimulate AMPARs and KARs (Wang et al., 2005).  Increase intracellular calcium can
also activate calcium/calmodulin-dependent protein kinase II (CamKII), which stimulates
the insertion of additional AMPARs and KARs in the neuronal membrane and which
enhances Glu release via synapsin phosphorylation (Fink and Meyer, 2002).  Finally,
calcium-induced CamKII activation can activate nitric oxide synthase, also resulting in
increased Glu release (Fink and Meyer, 2002).  Metabotropic Glu receptors can be further
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1 5classified into mainly postsynaptic Group I receptors (e.g. mGluR , mGluR ), mainly
2 3presynaptic Group II receptors (e.g. mGluR , mGluR ), or mainly presynaptic Group III
4 6 7 8receptors (e.g. mGluR , mGluR , mGluR , mGluR ) (Ozawa et al., 1998).  When
activated by a ligand, mGluRs activate guanine nucleotide-binding protein (G-protein)
linked cascades that ultimately increase intracellular concentrations of inositol 1,4,5-
triphosphate (IP3), diacylglycerol (DAG) and cyclic adenosine monophosphate (cAMP)
i(Lambert, 1993).  Presynaptic mGluRs serve to decrease NMDAR activity via G  protein
qwhile postsynaptic mGluRs serve to increase NMDAR activity via G  proteins (Lambert,
1993). 
1.1.3.1.3  Glutamate degradation 
Following presynaptic release and activation of postsynaptic Glu receptors, Glu is
catabolized by several pathways which mirror the anabolic pathways.  Firstly, Glu can be
converted to glutamine via glutamine synthase, a component of the glutamine cycle (as
reviewed in Feldman, 1997).  Secondly, transaminase can function bi-directionally and
thereby convert an á-keto acid and Glu to á-ketoglutarate and an á-amino acid (as
reviewed in Feldman, 1997).  Finally, a novel mechanism exists which involves the
conversion of Glu to á-ketoglutarate via Glu dehydrogenase (as reviewed in Feldman,
1997).  In addition to the three catabolic pathways of Glu degradation, excitatory
amino-acid transporters are also able to serve as reuptake mechanisms to transport Glu
from the synapse into presynaptic neurons and glial cells (as reviewed in Feldman, 1997).
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1.1.3.1.4  Glutamate in CNS development
Glutamate is the primary excitatory neurotransmitter in the mammalian CNS and
approximately half of all neurons in the brain are classified as Glu-releasing (Ozawa et
al., 1998).  Proper levels of Glu signaling in the developing brain are critical as Glu has
been shown to play an important role in regulating neuronal survival, differentiation and
synaptogenesis (McDonald and Johnston, 1990).  Altered Glu signaling in the developing
brain, specifically through treatment with NMDAR antagonists, has been shown to
disrupt proper development by triggering apoptosis (Ikonomidou et al., 2001) and by
causing subjects to display various behavioural abnormalities, including prepulse
inhibition (PPI) deficits and increased locomotor activity, well into adulthood (Harris et
al., 2003; Kawabe et al., 2007).  In addition to NMDAR-mediated effects on
development, KARs have also been shown to significantly affect the developing brain, as
several persistent behaviours changes including alterations in social behaviour (Ryan et
al., 2011), reward seeking behaviour (Burt et al., 2008a), and latent inhibition (Adams,
2009), among others, have been observed following neonatal treatment with low doses of
domoic acid (DOM), a KAR agonist, from post-natal day (PND) 8-14.  The previous
findings have contributed to the development of a novel animal model of schizophrenia
that is produced by the administration of a Glu agonist, a neurotransmitter that has been
extensively implicated in the pathogenesis of schizophrenia (Buka et al., 2001; Dracheva
et al., 2001; Meador-Woodruff et al., 2001; Gluck et al., 2002; Bauer et al., 2008;
Malaspina et al., 2008).
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1.1.3.1.5  Role of glutamate in schizophrenia
The findings that Glu is the primary excitatory neurotransmitter in the CNS (Ozawa et al.,
1998) and that alterations in Glu tone during development can have significant effects on
neuroanatomy (McDonald and Johnston, 1990) and behaviour (Harris et al., 2003;
Kawabe et al., 2007) are significant in that they demonstrate the impacts of
developmental insults to the Glu system in terms of significant, persistent behavioural
abnormalities.  Such observations have led to early Glu dysfunction being implicated in
disorders such as schizophrenia.  The potential role of Glu dysfunction in schizophrenia
has been demonstrated by various studies showing that factors including maternal stress
and prenatal viral infections, both of which are associated with altered Glu signaling, are
also associated with schizophrenia (Buka et al., 2001; Malaspina et al., 2008).  Also,
various studies have demonstrated Glu system alterations in the post-mortem brains of
aged individuals diagnosed with schizophrenia.  These include decreased PFC KAR
binding and alterations in KAR subunit expression (Meador-Woodruff et al., 2001),
increased expression in the PFC of various NMDAR subunits (Dracheva et al., 2001),
Glu transporters (Bauer et al., 2008) and phosphate-activated glutaminase, an enzyme that
converts glutamine to Glu (Gluck et al., 2002).  However, some of the first and most
significant support for the role of Glu in schizophrenia came from the observation that
phencyclidine (PCP) and ketamine, both of which are NMDAR antagonists, can elicit
positive, negative, and cognitive symptoms in both humans and animal models (Geyer et
al., 1984; Sams-Dodd, 1997; Adams and Moghaddam, 1998; Adler et al., 1999a;
Rasmussen et al., 2007).  Other studies revealed that treatment with PCP decreases DA
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activity in the prefrontal lobes and that this hypoactivity was responsible for the
manifestation of negative and cognitive symptoms (Jentsch et al., 1999).  While the DA
hypothesis of schizophrenia, which proposes that DA hypoactivity at D1 receptors in the
PFC underlies both cognitive and negative symptoms while DA hyperactivity at D2
receptors in subcortical structures underlies positive symptoms, has been the most
influential theory of schizophrenia, this discovery helped pave the way for the Glu
hypothesis of schizophrenia (Olney et al., 1999).  The Glu hypothesis proposes that
NMDAR hypofunction is responsible for various aspects of the symptomatology
observed in schizophrenia (Olney et al., 1999).  However, as the Glu system, which acts
through NMDARs, AMPARs, and KARs, can serve to modulate the release of DA
(Kretschmer et al., 1999) these two hypotheses are not mutually exclusive and can
compliment each other, as will be discussed in subsequent sections.
1.1.3.2  Dopamine
Dopamine is a catecholamine neurotransmitter that is important in various processes
including cognition (as reviewed in Nieoullon, 2002), motivation (as reviewed in Wise,
2004), reward (as reviewed in Ikemoto, 2007), and motor functioning (Brück et al.,
2001).  Dopaminergic abnormalities have been implicated in various disorders including
Parkinson’s disease (Leenders et al., 1986; Frost et al., 1993), attention-deficit
hyperactivity disorder (LaHoste et al., 1996; Dougherty et al., 1999), and schizophrenia
(Seeman et al., 1993; Laruelle et al., 1996; Lieberman, 2004).  The association between
aberrant DA pathways and schizophrenia has been investigated extensively following
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early findings that drugs which function as dopamine antagonists can treat schizophrenia
symptoms, leading to both the DA hypothesis of schizophrenia and to the development of
novel various treatment regimes, including improved antipsychotic drugs, which
modulate the DA system (Kapur et al., 2000; Potkin et al., 2003).
1.1.3.2.1  Biosynthesis of dopamine
The synthesis of DA is dependent on phenylalanine crossing the blood-brain barrier via
L-type amino acid transporters, a process that occurs in competition with the uptake of
tryptophan (as reviewed in Elsworth and Roth, 1997).  Following the uptake of
phenylalanine, phenylalanine hydroxylase converts phenylalanine to tyrosine, which is
then converted to L-3,4-dihydroxyphenylalanine (DOPA) by tyrosine hydroxylase (as
reviewed in Elsworth and Roth, 1997).  DOPA is subsequently transported into
presynaptic vesicles via vesicular monoamine transporter (VMAT), where aromatic-L-
amino acid decarboxylase functions to convert DOPA to DA (as reviewed in Elsworth
and Roth, 1997).  While this marks the end of the biosynthetic pathway in DA neurons,
other adrenergic and noradrenergic neuronal populations contain additional enzymes to
further modify DA into norepinephrine and, in turn, epinephrine (as reviewed in Elsworth
and Roth, 1997).
1.1.3.2.2  Dopamine pathways
The DA system can be understood as four main pathways, with these pathways
originating at the site of DA cell body localization, namely the substantia nigra, the
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ventral tegmental area (VTA), and the arcuate nucleus of the mediobasal hypothalamus
(as reviewed in Feldman, 1997).  Dopaminergic cells which are located in the substantia
nigra project to the striatum of the basal ganglia, forming the nigrostriatal system (as
reviewed in Feldman, 1997).  The nigrostriatal system functions in motor control and
damage to this system is associated with Parkinson’s disease (Graybiel et al., 1990). 
Dopaminergic cells which are located in the VTA can project to either the limbic system
(e.g. hippocampus, amygdala, nucleus accumbens (NAcc), etc.), forming the mesolimbic
system, or to the cortex, forming the mesocortical pathway (as reviewed in Björklund and
Dunnett, 2007).  The mesolimbic system functions in motivation and reward-based
behaviour (Wightman and Robinson, 2002) while the mesocortical pathway involves
higher cognitive functions (Moghaddam et al., 1997).  Finally, DA cells in the arcuate
nucleus of the mediobasal hypothalamus project to the median eminence of the
hypothalamus, thereby forming the tuberoinfundibular pathway which controls the release
of prolactin from the anterior pituitary gland (as reviewed in Vallone et al., 2000).
1.1.3.2.3 Dopamine receptor system
Dopaminergic receptors are classified into two main categories: D1-like receptors and
D2-like receptors (as reviewed in Feldman, 1997).  The D1-like receptor family, which
scontains both the D1 and D5 receptors, is linked to G  G-proteins which function to
increase adenylate cyclase-based formation of cAMP (as reviewed in Sidhu and Niznik,
2000).  The D2-like receptor family, which contains the D2, D3, and D4 receptors, is
ilinked to G  G-protein which serves a role which is antagonistic to the D1-like receptor
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family by decreasing adenylate cyclase-based formation of cAMP (as reviewed in Sidhu
and Niznik, 2000).  Additionally, D2 is unique among the DA receptors in that it serves
as the autoreceptor, thereby regulating presynaptic DA release (as reviewed in Sidhu and
Niznik, 2000).
1.1.3.2.4 Dopamine degradation 
The two main mechanisms for DA degradation include reuptake, the primary mechanism,
and enzymatic degradation.  Reuptake is accomplished by dopamine transporter (DAT)
and norepinephrine transporter (NET), both of which are presynaptic transporters which
allow the recycling of pre-synthesized DA (as reviewed in Feldman, 1997).  Enzymatic
degradation involves the actions of both monoamine oxidase (MAO) and COMT (as
reviewed in Elsworth and Roth, 1997).  While MAO is effective in reducing DA levels,
its localization on mitochondrial membranes prevents direct synaptic degradation of DA,
although there is a net decrease in DA as a result of the actions of MAO (as reviewed in
Feldman, 1997).  However, COMT exists in both cytosolic and membrane-bound forms,
thereby allowing for both the intracellular and extracellular destruction of DA (as
reviewed in Feldman, 1997).
1.1.3.2.5  Dopamine in CNS development
The DA system has an extended developmental period which, in the rat, extends from
embryonic day (ED) 12, which is approximately equivalent to week five of gestation in
human development, through to PND 14, which is approximately equivalent to the third
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trimester in human development (Ugrumov, 1997).  However, both post-mortem studies
and in vivo position emission tomography (PET) studies have shown that peak cortical
and subcortical DA tone is not reached until early adulthood (McGeer and McGeer,
1981;Wong et al., 1984).  Thus, if early alterations to the DA system occur when the
system is developing between E12 and PND14, and if such alterations persist,
behavioural abnormalities may not become apparent until later periods, such as early
adulthood, when DA signalling is more prominent.  In fact, studies have shown that early,
selective, 6-hydroxydopamine (6-OHDA)-induced degeneration of DA terminals
produces abnormalities in anxiety levels and memory ability with treatment on PND4 or
PND10 producing stronger effects than treatment on ED13 or ED17 (Shabanov et al.,
2005).  Additionally, postnatal stress from PND1-13 has been shown to produce animals
who manifest increased DA metabolites when exposed to restraint stress in adulthood
(Cabib et al., 1993), thereby confirming that various early manipulations, including 6-
OHDA-induced DA terminal degeneration and stress exposure, can produce long-term
DA abnormalities that persist into adulthood.  These findings are significant as they
demonstrate that early neurodevelopmental factors, which are believed to be involved in
the pathogenesis of schizophrenia, may affect DA development and contribute to the later
manifestations of the disease in early adulthood.
1.1.3.2.6  Role of dopamine in schizophrenia
The first evidence that schizophrenia is associated with alterations in the DA system came
from the observation that chlorpromazine, a DA antagonist used for its anxiolytic
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properties, was effective in treating the positive symptoms of schizophrenia (as reviewed
in Carlson, 2007).  This discovery led to the development of various other DA antagonist
drugs that became classified as antipsychotic drugs.  It was also observed that DA
agonists such as amphetamine and cocaine are effective in producing positive symptoms
of schizophrenia and that these symptoms are counteracted by treatment with
antipsychotics (as reviewed in Carlson, 2007).  These observations support the argument
that antipsychotic drugs exert their effects by blocking DA transmission, specifically at
D2 receptors.  Subsequent studies revealed that the mesolimbic DA system, with
projections from the VTA to the NAcc and amygdala, is likely to be the site of DA
hyperactivity underlying the positive symptoms of schizophrenia (Laruelle et al., 1996). 
However, cognitive symptoms appeared to differ from positive symptoms in that
cognitive symptoms were unaffected by treatment with antipsychotics and thus unlikely
to be due to DA hyperactivity at D2 receptors (as reviewed in Feldman, 1997).  In fact,
research showed that cognitive symptoms were associated with DA hypoactivity at D1
receptors in the PFC (as reviewed in Abi-Dargham and Moore, 2003).  Evidence of both
DA hyperactivity and hypoactivity led to the development of a new class of drugs, the
atypical antipsychotics, which function either through more complex binding profiles or
as partial DA agonists which are able to both reduce DA activity in the overstimulated
NAcc and also increase DA activity in the understimulated PFC (Lieberman, 2004). 
Aripiprazole is one such partial agonist which has a higher affinity than DA for DA
receptors but elicits less of a response than the natural ligand (Lieberman, 2004).  Thus,
aripiprazole acts as an antagonist in the overstimulated NAcc and as an agonist in the
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understimulated PFC.  
1.1.3.2.7 Relationship between glutamate and dopamine
The two most prominent neurotransmitters that have been implicated in schizophrenia are
Glu and DA, leading to both the Glu hypothesis of schizophrenia and the DA hypothesis
of schizophrenia.  However, these two explanations are not mutually exclusive.  In fact,
the idea of hypofrontality has emerged with integrates both Glu and DA alterations and
proposes that prefrontal Glu hypoactivity, due to NMDAR hypofunction, leads to both
DA hyperactivity in the mesolimbic pathway and hypoactivity in the mesocortical
pathway (as reviewed in Carlson, 2007).  Such alterations in the DA system are of
relevance to schizophrenia as DA hyperactivity in the mesolimbic system is speculated to
underlie the manifestation of positive symptoms while DA hypoactivity in the
mesocortical system is speculated to underlie the manifestation of negative and cognitive
symptoms (Stone et al., 2007).  It is hypothesized that prefrontal NMDAR hypofunction
is the result of genetic factors and/or some environmental insult and that reduced Glu tone
from neurons in the PFC can result in downstream alterations in the DA system (Olney et
al., 1999).  Glutamatergic neurons in the PFC project to the VTA where they innervate
both DA neurons and GABA-containing neurons.  In turn, the DA neurons in the VTA
project back to the PFC and the GABAergic neurons either project directly to the NAcc
or innervate other DA neurons in the VTA that project to the NAcc.  Such an arrangement
of pathways would cause any decreases in prefrontal Glu activity to result in an
underactivition of GABAergic neurons in the VTA which, in turn, would result in
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disinhibition of DA neurons that project to the NAcc, thereby resulting in DA
hyperactivity in the NAcc.  Also, since the glutamatergic neurons in the PFC synapse on
DA neurons in the VTA, which project back to the PFC, decreased prefrontal Glu activity
would be a self-reinforcing process (as reviewed in Carlson, 2007).
In addition to the interaction between the Glu and DA systems in terms of hypofrontality,
alterations in Glu signaling can have a direct effect on DA neurons as many DA cell
bodies throughout the brain possess Glu receptors (Ozawa et al., 1998).  Therefore,
increased Glu activity during brain development may lead to over-activation of such DA
neurons and, if NMDAR and AMPAR containing unedited GluR2 subunits are activated,
may result in calcium influx into DA neurons (Swanson et al., 1997).  In addition to the
role of NMDARs and AMPARs in the flux of calcium, KARs, which are targeted by
DOM, are also able to transport calcium into the intracellular space in cases where either
GluR5 or GluR6 subunits that have not undergone post-transcriptional RNA glutamine-
to-arginine editing are present (as reviewed in Vissel et al., 2001).  Once present
intracellularly, calcium is able to activate a number of signal transduction cascades that
can ultimately lead to changes in gene expression (Purves et al., 2008).  Thus, it is
possible for alterations in the Glu system to lead to alterations in gene expression in DA
cells.
The idea of hypofrontality and the potential effects of NMDAR activation on gene
expression in DA cells are examples of interactions between the Glu and DA systems and
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highlight potential ways in which treatment with Glu agonists such as DOM may affect
DA transmission.  Additionally, alterations in these neurotransmitter systems have served,
and continue to serve, to guide research on schizophrenia in terms of animal models.
1.2  Animal models
Animal models involve simulating a human condition in a non-human species and are
therefore useful for testing novel treatments and for improving our understanding of
various disorders (Geyer and Markou, 2000).  There are currently a number of accepted
animal models of schizophrenia, most notably (i) the neonatal hippocampal lesion model
(Lipska et al., 1995), (ii) pre-natal immune challenge models (Zuckerman and Weiner,
2003), (iii) the PCP model (Rasmussen et al., 2007) and (iv) various genetic models
(Hikida et al., 2007; Pletnikov et al., 2008). 
1.2.1  Measures of reliability and validity in animal models
In order for an animal model to be beneficial it must be both reliable and valid. 
Reliability refers to the consistency with which the results of a given study are obtained,
while validity, of which there are various types, refers to how well the model maps onto
the specific clinical question.  While there are various types of validity that define the
usefulness of animal models, the significance of a model does not necessitate that all
validity criteria are met, since the relevant criteria for a model are largely dependent on
the purpose of the model.  However, while acknowledging that different categories of
validity are relevant for different studies, the four most commonly accepted categories of
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validity for animal models of human conditions include (i) face validity, (ii) construct
validity, (iii) etiological validity, and (iv) predictive validity (Geyer and Markou, 2000). 
Face validity refers to the similarity between the behavioural manifestations in a model
and behavioural manifestations of a given disease in the clinical population (Geyer and
Markou, 2000).  However, face validity must often be supplemented with construct
validity, which refers to the accuracy with which a test measures that which it is intended
to measure (Geyer and Markou, 2000).  For example, construct validity involves the
identification and elimination of alternative explanations for a given experimental
finding.  This type of validity is often difficult to establish since the concept of what a test
should be attempting to measure changes as advancements improve our understanding of
the human condition.  An animal model with etiological validity involves recapitulating
the clinical etiology (Geyer and Markou, 2000).  Again, etiological validity is often
difficult to establish since the etiology of the human condition is often poorly understood. 
Predictive validity, which is considered by some to be the most important form of
validity, is often used to refer to the ability of a model to identify novel therapeutic
compounds (Geyer and Markou, 2000).  Two lesser known forms of validity include
convergent validity and discriminant validity.  Convergent validity refers to similarities
between a given model and other models while discriminant validity refers to unique
features of a given model (Geyer and Markou, 2000). 
1.2.2  Modelling schizophrenia symptoms in rodents
The symptomatology of schizophrenia is extremely diverse and is characterized by (i)
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positive symptoms; marked by the presence of abnormal behaviours (e.g. delusions), (ii)
negative symptoms; marked by absence of normal behaviours (e.g. social withdrawal) or
(iii) cognitive symptoms; marked mainly by learning and/or memory deficits (e.g.
working memory dysfunction) (DSM-IV-TR, 2000). 
1.2.2.1  Positive symptoms
Positive symptoms of schizophrenia refer to the presence of abnormal behaviours such as
hallucinations, delusions, disordered thought, and psychomotor agitation, and are
believed to be due in part to DA hyperactivity in the mesolimbic pathway (Stone et al.,
2007).  While animal models are clearly unable to mimic certain positive symptoms, such
as hallucinations and delusions, psychomotor agitation and disordered thought are more
reproducible (Rueter et al., 2004; Wedzony et al., 2008).  Additionally, it is thought that
impaired sensorimotor gating and an inability to filter out irrelevant information, which
may be the core components of disordered thought, may also underlie hallucinations and
delusions (Braff et al., 1977; Adler et al., 1982).  Therefore, since impaired sensorimotor
gaiting and deficits in filtering out irrelevant information can be easily assessed in rodents
through tests of PPI and latent inhibition, respectively, these tests have become gold-
standard behavioural tests in animals as they appear to assess the core functional
disturbances of the disorder, while eliminating the need to assess clinical symptoms such
as hallucinations and delusions.
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1.2.2.2  Negative symptoms
Negative symptoms of schizophrenia refer to the absence of normal behaviours and
include blunted affect, anhedonia, alogia, and social withdrawal (DSM-IV-TR, 2000). 
The neurobiological basis of negative symptoms is believed to be due, in part, to DA
hypoactivity in the mesocortical pathway (Stone et al., 2007).  The main negative
symptoms which can be demonstrated in animal models include social withdrawal (Audet
et al., 2009; Ryan et al., 2009), the gold-standard in terms of negative symptomatology,
anhedonia (Daenen et al., 2003), and emotionality (Koike et al., 2009).  Social withdrawal
is often assessed either using a dynamic interaction whereby two rodents are placed in an
open field chamber with the amount of interaction time spent by the subjects being
measured (Audet et al., 2009).  Alternatively, a more passive interaction can be
performed by placing a test subject in a two-chamber arena which has a divider separating
the test subject from a stimulus rat.  This allows for the assessment of the amount of time
spent by the test subject in proximity to the stimulus rat as a measure of social behaviour
(Ryan et al., 2009).  Other methods for assessing negative symptoms include the use of an
elevated plus maze which has two arms with walls and two arms without walls (Koike et
al., 2009).  The amount of time spent by the subjects in the walls without arms provides a
measure of the emotionality of the rat.  Subjects who are less emotionally driven may
spent more time in the unprotected arms than do those who are more fearful.  Also,
anhedonia can be assessed by placing an animal in a pool without an escape platform and
measuring the length of time before the animal aborts attempts to escape (Daenen et al.,
2003). 
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1.2.2.3  Cognitive symptoms
The cognitive symptoms of schizophrenia are considered to include attentional deficits,
learning and memory impairments, and abnormalities in executive functioning (DSM-IV-
TR, 2000).  The significance of neurocognitive symptoms in schizophrenia is supported
by the findings that cognitive impairments are present, to some degree, in almost all
patients (Green et al., 2004), and that cognitive symptom category is most strongly
correlated with functional ability (Green, 1996).  Cognitive symptoms are perhaps most
easily replicated in animal models, and include tests such as (i) PPI (Braff and Geyer,
1990; Adams et al., 2008), (ii) latent inhibition (Alves and Silva, 2001; Zuckerman and
Weiner, 2003), (iii) the radial 8-arm maze (Enomoto and Floresco, 2009), (iv) the puzzle
box (Abdallah et al., 2011), and (v) digging tasks (Eggerton et al., 2005). 
Pre-pulse inhibition is one of the more basic assessments of cognitive functioning as it
involves reflexive behaviour.  Pre-pulse inhibition, which, along with latent inhibition,
are two gold-standard behavioural tests of schizophrenia, is an assessment of the
sensorimotor gating reflex, which shows great consistency across species (Swerdlow et
al., 1999).  Pre-pulse inhibition involves the normal suppression of the acoustic startle
reflex when pre-exposed to a lower, non-startling pre-pulse tone.  Normally, exposure to
a pre-pulse, which is not consciously discernible from the pulse, decreases the response to
a subsequent startle pulse.  However, schizophrenia is associated with impaired PPI, such
that the pre-pulse does not decreased the response to the subsequent startle pulse (Grillon
et al., 1992).  
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Assessment of latent inhibition, which is a phenomenon of basic classical conditioning, is
another method of assessing lower-level cognitive ability.  Latent inhibition involves the
ability to filter out irrelevant information and occurs when pre-exposure to a stimulus,
which is not associated with a noteworthy outcome (e.g. aversive event), prevents the
later conditioning of the original stimulus with a subsequent event (e.g. aversive event). 
For example, a subject may be pre-exposed to a sucrose solution, with no adverse
outcome (e.g. shock exposure).  Subsequently, if the subject, while consuming sucrose,
was to receive a mild shock, the association between the sucrose solution and the shock
would be weak compared to the association that would be established if their first
exposure to the sucrose solution had been paired with a shock.  Those with schizophrenia
demonstrate impaired latent inhibition, with strong associations being formed even with
numerous pre-exposures without an adverse outcome (Gray et al., 1995).  
The radial 8-arm maze, a more complex task than PPI or latent inhibition, involves spatial
working memory.  Impaired working memory is now recognized as a possible core
cognitive symptom in schizophrenia and can be assessed in the radial 8-arm maze by
baiting all eight arms with food and determining the number of arm choices that are made
before the food reward is received from all arms, with lower total number of arm choices
indicating superior spatial working memory.
The puzzle box and digging task involve the assessment of more high-level cognitive
processes.  As of yet, these paradigms have not been frequently used to evaluate higher-
31
order cognitive processes in animal models of schizophrenia.  One reason for this may be
that, when compared to PPI and latent inhibition, both the puzzle box and digging task
are quite time-intensive for the experimenter.  However, since higher-order cognition is
known to be affected in schizophrenia (Bustini et al., 1999; Pantelis et al., 2009),
assessing models with these two tasks may better inform researchers about the nature of
cognitive deficits that are present in various animal models of schizophrenia.  In turn,
should there prove to be cognitive changes in these tasks, they are ideal targets for
assessments of predictive validity, given that cognitive symptoms are known to have the
most significant effect on daily functioning in those with schizophrenia and are thought to
be core in the manifestation of the disorder (Rabinowitz et al., 2012).
The puzzle box is able to assess short-term memory ability, long-term memory ability,
and problem solving ability.  This is accomplished by placing a subject in an aversive,
brightly lit chamber which is separated from a more comforting, dark chamber.  In order
to enter the less aversive chamber, the subject must discover how to dislodge the barrier
that separates the chambers.  Additionally, subjects are tested a number of times per day
and the barrier changes each day over the three days of testing, thereby allowing for the
assessment of problem-solving, short-term memory, and long-term memory.  
Finally, cognitive flexibility can be assessed using a digging procedure known as the
attentional set-shifting paradigm.  Cognitive flexibility involves shifting attention from
one focus to another (Owen et al., 1993; Konishi et al., 1998), involves inhibitory control
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and working memory components (Pantelis et al., 2009), and has been shown to be
disrupted in various populations (Dias et al., 1996; Birrell and Brown, 2000; Rodefer et
al., 2005).  In this test, subjects are provided with two bowls, one of which is baited with
food, with bowels varying in terms of the digging medium (M) that they contain and their
odour (O).  In order to solve various discrimination problems and obtain a food reward,
subjects must learn to attend to a relevant cue (i.e. digging M in a bowl) while ignoring an
irrelevant cue (i.e. O of a bowl).  The task is to use the cues of digging M or O to select
the “correct” (i.e. baited) bowl.  Subsequently, the relevant and irrelevant cues are then
shifted and cognitive flexibility is assessed. This is conceptually equivalent to a human
neuropsychology test known as the Wisconsin Card Sorting Task, which often identifies
abnormalities in cognitive flexibility and attentional set-shifting in the clinical population
(Everett et al., 2001).
1.2.3  Rodent models of schizophrenia
Animal models of human conditions are intrinsically difficult to develop, with
schizophrenia being a particularly strong example due, in part, due to the diagnostic
symptoms of schizophrenia (e.g. hallucinations and delusions).  However, the
heterogeneity of schizophrenia provides researchers with a variety of behaviours that can
be exhibited in rodents while also serving to focus researchers on core neurobehavioural
symptoms, including positive symptom behaviours (e.g. psychomotor agitation and
disordered thought), negative symptom behaviours (e.g. social withdrawal, anhedonia,
and abnormal emotionality), and cognitive symptoms behaviours (e.g. working memory
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deficits, PPI deficits, impaired latent inhibition, altered problem solving, and decreased
cognitive flexibility).  These models can take various forms, but the most prominent
categories are genetic models, lesion-based models, drug-induced models, and
developmental models).
1.2.3.1  Genetic based models
While several potential susceptibility genes for schizophrenia have been recently
identified (e.g. genes for dysbindin, neuregulin 1, DISC-1, and D-amino-acid oxidase) (as
reviewed in Owen et al., 2005), the DISC-1 animal model seems to hold the most
promise.  Functionally, DISC-1 is believed to be involved in regulation of neuronal
proliferation, neuronal process growth, and neuronal adhesion (Miyoshi et al., 2003;
Sasaki et al., 2005).  Disrupted in schizophrenia-1 animal models have shown face
validity through studies demonstrated increased locomotor activity, enlarged ventricles,
and altered PPI (Hikida et al., 2007).  However, while the DISC-1 animal model seems to
have a degree of etiological validity due to the genetic association between DISC-1 and
schizophrenia, it is recognized that schizophrenia is the result of a complex interplay of
many genetic and environmental factors, with no single etiological factor being
responsible.  Therefore, it is important to both recognize the importance of the DISC-1
genetic model and to attempt to develop additional models with improved etiological
validity. 
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1.2.3.2 Lesion based models
In terms of neonatal lesion-based models, the neonatal ventral hippocampal (VH) lesion
model has received the most attention.  The VH lesion model appears to satisfy construct
and face validity criteria as it has been shown to produce increased locomotor behaviour
in response to various stimuli (e.g. novelty, forced swimming, and amphetamine
exposure) (Lipska et al., 1993), alterations in PPI (Lipska et al., 1995), impaired latent
inhibition (Greksch et al., 1999), and social withdrawal (Becker et al., 1999). 
Additionally, the VH lesion model has shown stress-induced alterations in levels of both
DA and its metabolites in the NAcc (Lillrank et al., 1999).  Predictive validity has also
been shown in the VH lesion model as haloperidol has been observed to reverse
abnormalities in locomotor behaviour (Lipska et al, 1993) and clozapine has been
observed to reverse PPI abnormalities (Le Pen and Moreau, 2002).  This model is also
attractive due to its developmental nature, thereby supporting an argument for etiological
validity.  However, while the VH lesion model appears to exhibit etiological, face,
construct, and predictive validity, the extent of damage inflicted in this model is not
representative of hippocampal abnormalities in the clinical population, which mainly
involve more subtle alterations to neuronal number, structure, connectivity, and
neurochemical alterations (Gao et al., 1997; Zaidel et al., 1997; Webster et al., 2002;
Zhang and Reynolds, 2002) rather than gross structural lesions.
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1.2.3.3  Drug-induced models
Drug-induced models, particularly those involving DA agonists, have had significant
appeal in schizophrenia research, largely based on similarities between their mechanism
of action and the DA model of schizophrenia.  Face validity and predictive validity have
been shown with amphetamine administration, which stimulates DA release, as studies
have demonstrated that amphetamine-induced hyperlocomotion and stereotypy are both
reversible with antipsychotic treatment (Megens et al., 1992).  Additionally,
antipsychotic-reversible abnormalities have been shown in terms of PPI (Abekawa et al.,
2008).  Other DA-based drug-induced models involve the direct injection of DA
(Swerdlow et al., 1990) or DA agonists (Swerdlow et al., 1994), which can also produce
PPI deficits which are reversible with antipsychotic treatment.  While the various
pharmacological methods for increasing DA tone in the brain seem to satisfy the face and
predictive validity criteria, this relates predominantly to the positive symptoms of
schizophrenia.  In fact, the negative and cognitive symptoms of schizophrenia are more
associated with hypodopaminergia than hyperdopaminergia, thereby limiting the face and
predictive validity of DA drug-induced models to positive symptoms.  
Consequently, acute Glu-based models, which are able to mimic positive, negative, and
cognitive symptoms, have supplanted DA-based pharmacologic models.  The most
widely accepted Glu-based model involves acute injections of PCP, a non-competitive
NMDAR antagonist.  This treatment has been shown to produce behavioural symptoms
of schizophrenia such as hyperlocomotion (Adams and Moghaddam, 1998), social
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isolation (Sams-Dodd, 1997), impaired PPI (Geyer et al., 1984), and impaired attentional
set-shifting (Egerton et al., 2005).  Additionally, predictive validity is confirmed in the
PCP-model as PCP-induced hyperlocomotion, social isolation, and PPI deficits are
reversed with clozapine (Freed et al., 1980; Bakshi et al., 1994; Steinpries et al., 1994). 
Neurochemical abnormalities consistent with schizophrenia have also been observed
following acute PCP administration, including increased levels of DA and Glu in the PFC
and NAcc (Adams and Moghaddam, 1998).  However, despite the various advantages of
the PCP-model of schizophrenia, it is not able to satisfy the criteria of etiological validity,
thereby further limiting their usefulness in terms of identifying and characterizing the
underlying etiology and neurodevelopmental nature of schizophrenia.
1.2.3.4  Developmental models
Developmental models are somewhat unique in that they can include drug-induced
models, lesion models, or genetic models, so long as the experimental manipulation
occurs during animal development to produce symptoms at a later point.  Therefore, the
VH lesion model is not only a lesion-based model, but also a developmental model. 
Another well-studied developmental model involves neonatal non-competitive NMDA
receptor antagonism through the administration of dizocilpine, although the
administration dosage and time-period can vary somewhat between studies.  Regardless,
the neonatal dizocilpine model has been shown result in reduced hippocampal volume
and cell counts (Harris et al., 2003), PPI deficits (Harris et al., 2003), impaired spatial
working memory (Kawabe et al., 2007), and increased locomotor activity (Hoffman,
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1992), thereby demonstrating face validity. 
In addition to the ability of developmental models to produce behavioural alterations that
are characteristic of schizophrenia, the NMDAR antagonism model and neonatal VH
lesion model appear to reflect the neurodevelopmental nature of schizophrenia and
therefore appear to satisfy the criteria of etiological validity.  However, further
examination of these models leads to questions of the relevance of large lesions to the
hippocampus and of relatively high dose exposure to NMDAR antagonists with respect to
the types of insults that are likely to affect the clinical population.  Therefore, additional
animal models which involve more subtle brain insults must be developed.  Also, due to
the heterogeneous nature of the disorder, it is unlikely that any animal model will
effectively capture all relevant characteristics of schizophrenia (Powell and Miyakawa,
2006).  Therefore, in addition to the importance of novel animal models for improving
our understanding of the etiology of schizophrenia and to screen potential therapeutants,
novel models must be developed to more effectively mimic such a complex disorder. 
The current study focuses on further characterizing a novel animal model of
schizophrenia that involves subtle alterations in Glu signaling in the developing brain (see
Section 1.3).  
The current model (i.e. subcutaneous (s.c.) injections of 20 ìg/kg of DOM from PND 8-
14) has been shown to produce subjects that exhibit various behavioural, neurochemical,
and neuroanatomical alterations that are characteristic of schizophrenia without inducing
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gross structural lesions (Doucette et al., 2004; Bernard et al., 2007; Doucette et al., 2007;
Adams et al., 2008; Burt et al., 2008).  In addition to the face validity shown in the DOM
model, the model is advantageous as, based on our current understanding of
schizophrenia, it appears to satisfy the criteria of etiological validity as it is
developmental in origin and, unlike some alternative models, involves exposure to very
low doses of a neurotoxin that targets the Glu system, a system that has been shown to be
affected in the clinical population (Dracheva et al., 2001; Gluck et al., 2002; Bauer et al.,
2008). 
1.3  Domoic acid model of schizophrenia                                                                       
1.3.1  Domoic acid
Domoic acid, an amnestic shellfish toxin that is produced by Pseudo-nitzschia species,
gained prominence in 1987 following the consumption of contaminated Mytilus edulis
harvested around Prince Edward Island (Perl et al., 1987).  Effects of varying severity
were seen in those exposed to DOM, ranging from gastrointestinal symptoms to short-
term memory loss, seizures, and death (Perl et al., 1990).  Domoic acid is structurally
similar to KA and acts in a dose-dependent fashion, exerting its effects at lower doses via
KA receptors and, at higher doses, via a variety of Glu receptors (Tasker et al., 1996). 
1.3.2  Domoic acid exposure during development
Domoic acid has a short half-life and poorly penetrates the blood-brain barrier, thereby
reducing its toxicity in older individuals (Preston and Hynie, 1991).  However, the ability
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of DOM to enter the brain during development prior to blood-brain barrier development,
combined with its ability to cross the placenta, make DOM a more potent neurotoxin
during development (Jeffery et al., 2004).  In vivo, rodents exposed to DOM during
development have shown various persistent behavioural and neurobiological
abnormalities.  Behavioural alterations include seizure-like symptoms in response to a
novel spatial environment (Doucette et al., 2004), altered PPI (Adams et al., 2008),
altered latent inhibition (Adams, 2009a), and social withdrawal (Ryan et al., 2009). 
Neurobiological alterations involving increased mossy fiber sprouting (Bernard et al.,
2007) and decreased hippocampal glutamic acid decarboxylase 67 (GAD 67) and
parvalbumin (Gill et al., 2010) have also been seen.  Neonatal exposure to DOM has
generated interest as a novel animal model of schizophrenia due to its effects on the Glu
system, which is extensively implicated in schizophrenia, its developmental nature, and
the various behavioural and neurochemical abnormalities that result from early exposure.
1.3.3  Neonatal low-dose domoic acid exposure as an animal model of schizophrenia
Treatment with low doses of DOM (20 ìg/kg) from PND 8-14 has been shown to have
potential as a novel animal model of schizophrenia.  Support comes from studies
demonstrating that treatment with DOM produces statistically significant neurochemical
alterations in the hippocampus that are characteristic of schizophrenia, including changes
in BDNF (Doucette et al., 2004), TrkB receptors (Bernard et al., 2007), and GAD 67
(Adams, 2009).  Also, it has been demonstrated that treatment with DOM produces
statistically significant alterations in PPI (Adams et al., 2008) and latent inhibition
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(Adams, 2009), two “gold standard” behavioural tests for animal models of
schizophrenia, as well as in social withdrawal (McInnis, 2009; Ryan et al., 2009) and
emotionality (Doucette et al., 2007), both of which are negative symptoms of
schizophrenia.  Additionally, alterations have been seen in reward seeking behaviour
(Burt et al., 2008a; Burt et al., 2008b), which is considered to reflect a positive symptom
of schizophrenia, and in temporal memory ability, which is considered to reflect cognitive
symptomatology (Robbins, 2010).  
These behavioural manifestations of schizophrenia are associated with DA hyperactivity
in the mesolimbic DA system and hypoactivity in the mesocortical system, thus
suggesting that neonatal treatment with the KAR agonist DOM may produce persistent
alterations in the DA system.  The mechanisms through which DOM-induced
neurodevelopmental alterations could occur are numerous.  Ostensibly, an increase in
KAR activity during a critical period of development could alter the maturation and
expression of not only KARs but also other neurotransmitter systems, including the
GABA system and DA system, which depend on KAR activity (Rodríguez-Moreno and
Lerma, 1998).  For example, DOM-induced alterations in the DA system are plausible as
KARs, a subtype of iGluR on which DOM acts, appear to regulate the mesocorticolimbic
DA system by modulating DA release (Kalivas et al., 1989).  Thus, treatment with DOM
may cause excessive DA release which could, in turn, result in compensatory changes in
the mesocorticolimbic DA system.  Additionally, evidence suggests NMDAR
involvement in DOM-mediated effects on conditioned O preference (Tasker et al., 2005). 
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This finding is significant in that NMDAR can flux calcium ions following the
displacement of a channel-blocking magnesium ion, a process which may be aided by
KAR activity (Purves et al., 2008).  The intracellular presence of calcium can then
activate various cascades that result in alterations in gene expression which, in turn, can
have persistent effects on protein production.  In addition to the indirect role of KARs in
activating NMDARs, which can then flux calcium,  KARs can also directly flux calcium,
specifically KARs that contain either GluR5 or GluR6 subunits that have not undergone
post-transcriptional RNA glutamine-to-arginine editing (as reviewed in Vissel et al.,
2001).
Thus, while the exact mechanism of action is undetermined, the regulatory role of KARs
in the mesocorticolimbic DA pathway and the involvement of both non-edited KARs and
NMDARs in calcium flux suggests that neonatal treatment with DOM can produce
persistent alterations in the DA system.  Such alterations in the DA system may also
manifest as cognitive dysfunctions such as impaired attentional set-shifting, a cognitive
symptom of schizophrenia.
The current study was conducted to further examine the potential of DOM treatment in
producing an animal model of schizophrenia by assessing the face validity, construct
validity, and etiological validity of the model.  Face validity was further characterized
using the attentional set-shifting and puzzle box paradigms to assess mPFC-dependent
higher-order cognitive functions which have been shown to be altered in the clinical
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population.  These mPFC-dependent behaviours have been associated with altered DA
tone, therefore the behavioural assessment was followed with immunohistochemical
analyses of D1 receptor, D2 receptor, and DAT in the mPFC in an attempt to understand
previous behavioural findings and any current behavioural findings (i.e. construct
validity).  Finally, after assessing behavioural alterations and any neurobiological
contributions to these behaviours, potential mechanisms of both the neurobiological and
behavioural alterations were examined using immunohistochemistry to assess caspase-3,
which is an executioner caspase in the apoptotic pathway, in the mPFC (i.e. etiological
validity).  Therefore, the current study allowed for further examination of the potential of
DOM treatment in producing an animal model of schizophrenia by assessing mPFC-
dependent higher-order cognitive functioning (i.e. face validity), assessing DA markers
related to higher-order cognitive behaviours in the mPFC (i.e. construct validity), and
assessing caspase-3, a potential contributor to any behavioural and/or neurobiological
alterations following neonatal DOM treatment (i.e. etiological validity).
These studies were performed with the objective of characterizing neurochemical
abnormalities in the mPFC and possible cognitive abnormalities with the hypothesis that
DOM treatment would produce alterations in caspase-3 and DA marker staining in the
mPFC with consequent cognitive deficits in the attentional set-shifting and puzzle box
paradigms.
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Chapter 2 
Assessment of cognitive functioning in adult rats treated neonatally with domoic
acid
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Summary
Cognitive symptoms of schizophrenia involve learning and/or memory impairments and
abnormalities in executive functioning (Gold and Harvey, 1993).  More specifically,
findings include impaired processing speed (Schatz, 1998), reasoning (Corcoran, 2003),
working memory (Conklin et al., 2000), temporal memory (Schwartz et al., 1991),
vigilance (Mar et al., 1996), and social cognition (Hall et al., 2004).  Cognitive symptoms
have been often replicated in animal models using tests such as the radial 8-arm maze
(Enomoto and Floresco, 2009), PPI (Braff and Geyer, 1990; Adams et al., 2008), latent
inhibition (Alves and Silva, 2001; Zuckerman and Weiner, 2003), digging tasks (Egerton
et al., 2005), and the puzzle box (Abdallah et al., 2011).  The significance of
neurocognitive symptoms in schizophrenia is supported by the findings that cognitive
impairments are present, to some degree, in almost all patients (Green et al., 2004), and
that cognitive symptom category is most strongly correlated with functional ability in the
clinical population (Green, 1996). 
The extent to which cognitive symptoms affect the clinical population, combined with the
previous findings of behavioural abnormalities in animal models of schizophrenia using
both the puzzle box procedure and digging tasks, provides rationale for the current study. 
The current study was conducted in order to further examine the face validity of the
neonatal DOM model by determining the effects of neonatal DOM treatment on
attentional set-shifting ability using a digging task and on problem solving ability, short-
term memory, and long-term memory using the puzzle box paradigm.  Results showed
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statistically significant treatment effects in the attentional set-shifting task with DOM-
treated males completing the IDS task with fewer errors than SAL-treated male
counterparts.  Additionally, significant treatment effects were seen in the puzzle box
during trials assessing short-term memory and problem solving ability, as evidenced
through DOM-treated females completing trial (T) 2, T3, T4, and T10 more quickly than
DOM-treated males.
2.1  Introduction
Glutamate is the primary excitatory neurotransmitter in the mammalian CNS (Ozawa et
al., 1998)..  Proper levels of Glu signaling in the developing brain are critical as Glu has
been shown to play an important role in regulating neuronal survival, differentiation, and
synaptogenesis (McDonald et al., 1990).  Additionally, abnormal Glu transmission is
related to a variety of neurodegenerative diseases, including schizophrenia (Parsons et al.,
1998; Deutsch et al., 2001).
Past research in our laboratory has shown that alterations in Glu signaling by early
treatment with DOM, a KAR agonist, produces adult animals that manifest several
behavioural abnormalities and neurochemical alterations that are characteristic of
schizophrenia, including altered reward seeking (Burt et al., 2008), social withdrawal
(Ryan et al., 2011), and PPI deficits (Adams et al., 2008), which reflect each of the major
categories of symptoms of schizophrenia.  However, due to the heterogeneity of
schizophrenia and variability both between patients and between animal models in terms
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of symptomatology, it is important to fully characterize each model in order to better
understand the relationship between the mechanism by which the model was produced
and the resulting behavioural and neurochemical effects.  Additionally, complete
evaluation of the wide array of cognitive domains in a model may provide insight into the
diversity of cognitive patterns that may categorize various subcategories of schizophrenia.
Higher-end cognitive symptomatology can be assessed by examining attentional-set
shifting ability.  Attentional-set shifting is a cognitive ability which involves shifting
attention from one focus to another (Owen et al., 1993; Konishi et al., 1998), involves
inhibitory control and working memory components (Pantelis et al., 2009), and has been
shown to be disrupted in various populations (Dias et al., 1996; Birrell and Brown, 2000;
Rodefer et al., 2005).  These include the clinical schizophrenic population (Jazbec et al.,
2007; Pantelis et al., 2009), rodents with damage to the mPFC, a key area involved in
schizophrenia (Birrell and Brown, 2000), macaques with damage to the lateral PFC (Dias
et al., 1996), and in NMDAR antagonist-induced animal models of schizophrenia
(Rodefer et al., 2005; Broberg et al., 2008).  
The digging task paradigm has proven useful for examining attentional set-shifting
abnormalities.  The digging task assesses the ability of subjects to solve various
discrimination problems in order to obtain a food reward by attending to a relevant cue
while ignoring an irrelevant cue (see Table 1).  The task is to use the cues of digging M or
O to select the “correct” (baited) bowl.  
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Table 1. Examples of the stimulus pairs that were used during testing in the digging task.
Odour Pairs Medium Pairs
Lemon and vanilla Mop and letters
Orange and banana Sponge and sand
Maple and coconut Imitation moss and white bedding
Almond and cinnamon Packing cardboard and brown bedding
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Subsequently, the relevant and irrelevant cues are then shifted and cognitive flexibility is
assessed (see Table 2). This is conceptually identical to the human neuropsychological
test known as the Wisconsin Card Sorting task (Lysaker et al., 1995; Haut et al., 1996).
Cognitive symptomatology can also be assessed by examining puzzle box performance,
which provides measures of short-term memory, long-term memory, and problem solving
ability.  In the clinical population, abnormalities have been observed in terms of short-
term memory (Goldberg et al., 1998), long-term memory (Hill et al., 2004), and problem
solving ability (Bustini et al., 1999).  Previous findings using the puzzle box are rather
limited due to its relatively recent development and have focused mainly on
characterizing strain differences (Lucurto et al., 2003; Lad et al., 2010).  However, a study
by Abdallah et al. (2011) has recently assessed the performance of mice from five animal
models of schizophrenia, including those treated sub-chronically with dizocilpine, those
lacking the GluR1 subunit of AMPARs, those over-expressing D2 receptors in the
striatum, and those with lesions to the mPFC or hippocampus.  Results showed impaired
performance in each animal models, with the effects being strongest in animals subjected
to hippocampal lesioning.  
The puzzle box procedure involves placing a subject in an aversive, brightly lit chamber
and measuring the latency for the subject to enter a less aversive, dark chamber. Passage
from one chamber to another is made progressively more difficult by decreasing the size
of the door separating the two chambers and by obstructing the door with various objects.
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Table 2. Example of a possible combination of stimulus pairs for a rat shifting from
digging M to O as the relevant dimension in the digging task.  The correct elements are
shown in bold with the S+ column representing the correct stimulus pairs and the S-
column representing the incorrect stimulus pairs.
Dimensions Element combinations
Discrimination Relevant Irrelevant S + S - 
Single
Discrimination
M sand marbles
Compound
Discrimination
M O sand/banana marbles/orange
sand/orange marbles/banana
Intradimensional
Shift
M O paper/maple gravel/peppermint
paper/peppermint gravel/maple
Reversal M O gravel/maple paper/peppermint
gravel/peppermint paper/maple
Extradimensional
Shift
O M lemon/cotton rum/sponge
lemon/sponge rum/cotton
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Testing consists of four Ts per day over a three day period, with the latency to enter the
goal box being measured and used as an indicator of problem solving ability, short-term
memory, and long-term memory.  Trials 1, 3, 6, and 10 are tests of problem-solving as
they involve the first exposure of subjects to obstacles on the way to the goal box (see
Table 3).  Trials 2, 4, 7, 8, 11, and 12 assess short-term memory as they involved re-
exposure to challenges that were recently faced (see Table 3).  Trials 5 and 9 assess long-
term memory as they involved re-exposure to challenges that were faced on the previous
day (see Table 3).
The current study employed both the digging task and the puzzle box procedure in order
to assess a variety of higher-order cognitive abilities such as attentional set-shifting
ability, short-term memory, long-term memory, and problem solving ability in order to
further characterizing the effects of neonatal administration of DOM, a Glu agonist, on
cognitive functioning.  This was done with the objective of assessing higher order
cognitive functions in the neonatal DOM model of schizophrenia with the hypothesis that
DOM-treated subjects would demonstrated cognitive deficits that are characteristic of
schizophrenia. 
2.2  Materials and methods
2.2.1  Experimental animals and injection procedure
All experiments were conducted on the offspring of untimed pregnant Sprague-Dawley
rats (Charles River Laboratories, St Constant, QC).  Dams were left undisturbed until the 
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Table 3.  Puzzle box testing procedure.
Day Trial Obstacle Measure
1 1 Large door Problem solving
1 2 Large door Short-term memory
1 3 Small door Problem solving
1 4 Small door Short-term memory
2 5 Small door Long-term memory
2 6 Bedding material Problem solving
2 7 Bedding material Short-term memory
2 8 Bedding material Short-term memory
3 9 Bedding material Long-term memory
3 10 Cardboard plug Problem solving
3 11 Cardboard plug Short-term memory
3 12 Cardboard plug Short-term memory
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day of birth which was defined as PND 0.  Within 24 hours of birth, each litter was culled
to up to 14 pups (7 male and 7 female, when possible).  Pups from each litter (n=10) were
pseudo-randomly assigned to either saline (n=20) or DOM (n=20) treatment groups with
an equal number of males and females in each treatment group. 
Domoic acid was obtained from Diagnostic Chemicals Ltd. (Charlottetown, PE) and the
drug was dissolved in sterile saline with injections being administered s.c. in a volume of
10 ml/kg.  From PND 8-14, pups were weighed, marked for identification (i.e. ear-
notched), and given a single daily s.c. injection of either 20 ìg/kg DOM or equal volume
of saline.  Previous work in our laboratory has shown that at this dose, no overt signs of
behavioural toxicity are apparent (Doucette et al., 2003).  Pups were weaned on PND 21
and singly-housed in a colony room maintained at approximately 22EC on a 12 hour
reverse light cycle with lights turning on at 07:00 h.  All animals received water and food
(Purina Lab Chow) ad libitum.  All testing was conducted during the dark phase of the
light/dark cycle with the experimenter blind to treatment.   All procedures were
conducted according to the guidelines established by the Canadian Council on Animal
Care and in accordance with the Animal Care Committee at the University of Prince
Edward Island.
2.2.2 Attentional set-shifting procedure
Subjects (n = 39; 10 male DOM, 10 male SAL, 10 female DOM, 9 female SAL) from
nine litters were assessed for attentional set-shifting ability using a digging task from
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PND 132-177. The attentional set-shifting paradigm assesses the ability of subjects to
solve various discrimination problems in order to obtain a food reward by attending to a
relevant cue (i.e. digging M in a bowl) while ignoring an irrelevant cue (i.e. O of a bowl). 
The task is to use the cues of digging M or O to select the “correct” (baited) bowl. 
Subsequently, the relevant and irrelevant cues are then shifted and cognitive flexibility is
assessed.  This is conceptually equivalent to a human neuropsychology test known as the
Wisconsin Card Sorting task.
Prior to testing, rats were food restricted for at least 7 days to ensure motivation to
perform the food-based task.  Subjects were weighed prior to food restriction, prior to
testing, and post-testing in order to monitor the effects of food restriction.  During the
first two days of the food restriction period, subjects were exposed to bowls with several
pieces of Sugar Crisp Cereal.  On subsequent food restriction days, the food reward was
buried in bedding material in order to expose subjects to the digging action that would be
required for successful completion of the task.  
The attentional set-shifting paradigm consisted of a one-hour habituation trial on the day
prior to the commencement of testing.  The first day of testing consisted of two single
discrimination tasks in order to familiarize subjects with attending to either digging M or
O in order to obtain a food reward.  The subsequent day, subjects faced a series of tasks
including a simple discrimination (SD) test, a compound discrimination test (CD), an
intra-dimensional shift (IDS) test, a reversal (REV) test, and an extra-dimensional shift
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(EDS) test.  Subjects were tested with each type of discrimination until a criterion value
of six consecutive correct choices were made, at which point they would progress to the
next type of discrimination.  Choices were defined as vigorous exploration of the digging
M.  This allowed subjects to approach each bowl and explore the O and texture of each M
without making a choice until the material became vigorously displaced.  Performing an
upper limit of 30 responses or failing to complete a given discrimination in two hours
resulted in the rat being removed from the chamber for 24 hours, at which point they were
returned to the chamber in order to complete the series of discriminations, starting with
the last discrimination problem that was successfully completed.  After reaching the
maximum allotted time on three separate occasions, a subject was no longer tested.
In the test of attention set-shifting ability, subjects were tested in a black plexiglass
chamber measuring 50 cm x 25 cm x 50 cm (length x width x height).  Subjects were
given a one-hour habituation trial on day one, two single discriminations (i.e. both
digging material and O) on day two, and a series of discrimination problems on day three. 
Testing involved access being given to two food bowls which differed from each other
with respect to two sensory domains, namely in terms of O and the digging M which they
contain.  One bowl contained a food reward, which was consistently associated with one
element of a sensory domain (i.e. reward in cup with M1, not M2), while the other
sensory domain was irrelevant (i.e. O1 and O2 do not predict food location).  Subjects
underwent a series of discrimination tests including a SD where one element was to be
chosen over another, a CD in which an irrelevant dimension was added, an IDS where the
55
same dimension was linked to reward but two new elements are presented, a reversal in
which the previously non-rewarded element was now the correct option, and finally an
EDS where the correct sensory dimension was changed.  For example, in a single test
session a subject could be faced with the following discriminations (see Table 2): First,
choose the bowl with M1 over the bowl with M2 (SD).  Subsequently, choose M1 over
M2 when an irrelevant O is linked to each food bowl (CD).  Then choose M3 over M4
while, again, an irrelevant O is linked to each food bowl (IDS).  The reversal trial then
occurs in which M4 should be chosen over M3, still ignoring the O.  Finally, attention
should be directed to O instead of digging M and O5 should be chosen over O6, with M5
and M6 being irrelevant.  Subjects were tested with each type of discrimination until
reaching a criterion level of 6 consecutive correct choices, at which point they progressed
to the next type of discrimination.  Nine cohorts of four subjects were constructed with
one member of each sex and treatment condition in each of the nine cohorts, and a tenth
cohort of three subjects was also constructed.  Each member of a particular cohort
received the same order of digging M and O throughout the set-shifting procedure while
no two cohorts received the same sequence.  An example of the arrangement of
discriminations is provided in Table 2.
2.2.3 Puzzle box procedure
Subjects (n=40) were assessed in the puzzle box following completion of the attentional
set-shifting procedure, from PND 153-189, with at least a week separating the two
behavioural testing paradigms for each subject.  The testing arena was constructed of
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plastic corrugated board and consisted of a brightly light start chamber measuring 70 cm
x 35 cm x 45 cm (length x width x height) which was separated from the darker goal
chamber measuring 40 cm x 35 cm x 45 cm (length x width x height) by a divider that
either had a large doorway measuring 22 cm x 11 cm (length x height) or a small doorway
measuring 10 cm x 11 cm (length x height) (see Figure 1).  The doorway could be
unobstructed, filled with bedding material that must be dug through, or filled with a
cardboard plug that must be pulled out of the opening.  Subjects were placed in the light
chamber and the latency to pass into the dark chamber was measured.  The negative
reinforcement of avoiding a large, brightly lit area served as motivation for subjects to
solve the various problems posed by the obstructions in the doorway in order to pass into
the goal box.
Testing consisted of four trials per day over a three day period (see Table 3).  On day 1,
T1 and T2 involved a large open doorway for easy entry into the goal chamber while T3
and T4 involved a small open doorway.  The subsequent day, T5 mirrored T3 and T4
while T6-8 involved the doorway being blocked by bedding material.  On the final day of
testing, T9 mirrored T6-8 and T10-12 involved the doorway being blocked by a
cardboard plug.  Subjects were given two minutes to enter the goal box on trials involving
an open doorway or bedding material and three minutes on trials involving a cardboard
plug.  Following entry into the goal box, subjects left for five minutes on T1 and one
minute on all other trials before being returned to the light chamber for the subsequent
trial.
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Figure 1.  Diagram of the puzzle box used during testing.
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2.2.4  Quantification of behaviour
All trials were video-recorded but scoring was performed concurrently with trial
performance.  Attentional set-shifting behaviour in the digging task was assessed by
measuring the number of trials required to reach the criterion level of 6 consecutive
correct choices for each type of discrimination.  This provided a measure of the ability of
subjects to shift attention from a previously learned rule to a new rule (i.e. cognitive
flexibility) in order to receive food rewards with impaired attentional set-shifting ability
being manifested as an increase in the number of trials to reach criterion.
Short-term memory, long-term memory, and problem solving ability in the puzzle box
procedure was assessed by measuring the latency to enter the goal box on each trial.  All
trials were video-recorded but scoring was performed manually at the time of testing. 
Trials 1, 3, 6, and 10 were tests of problem-solving as they involved the first exposure of
subjects to obstacles on the way to the goal box, thus increased latency to enter the goal
box on these trials would indicate problem-solving deficits.  Trials 2, 4, 7, 8, 11, and 12
assessed short-term memory as they involved re-exposure to challenges that were recently
faced, thus increased latency to enter the goal box on these trials would indicate short-
term memory deficits.  Trials 5 and 9 assessed long-term memory as they involved re-
exposure to challenges that were faced on the previous day, thus increased latency to
enter the goal box on these trials would indicate long-term memory deficits.  
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2.2.5  Data analyses
The attentional set-shifting task data was separated for sex based on the extent of sex-
specific findings in previous studies of the DOM model (Doucette et al., 2007; Adams et
al., 2008; Adams 2009b; Burt et al., 2008a; Robbins, 2010; Ryan et al., 2011), and was
analyzed using Student's t-tests for each trial type (PASW Statistics 18).  A result of p #
0.05 indicated statistical significance. 
The puzzle box data was also separated for sex and analyzed using  Student's t-tests for
each trial type (PASW Statistics 18).  A result of p # 0.05 indicated statistical
significance. 
2.3  Results
For the attentional set-shifting task, results of Student's t-tests revealed a statistically
significant treatment effect [t(11) = -2.021, p = 0.039] with DOM-treated males
completing the IDS task with fewer errors than SAL-treated males (see Figure 2).  No
other statistically significant effects were observed in this task.  See Table 4 for mean and
standard error of the mean (SEM) values for the attentional set-shifting paradigm. 
For the puzzle box task, results of Student's t-tests revealed statistically significant
treatment effects in female subjects for T2 [t(9.701) = -2.759, p = 0.021], T3 [t(9.198) = -
1.946, p = 0.042] , T4 [t(18) = -2.585, p = 0.019], and T10 [t(11.744) = -1.947, p = 0.038]
(see Figures 3-6).  In each of T2, T3, T4, and T10, DOM-treated females completed trials 
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Table 4.  Mean ± SEM number of trials to criterion for subjects treated neonatally with
DOM and SAL.  Asterisk indicates a statistically significant difference between treatment
groups (p # 0.05).  Superscript “y” indicates groups in which a single subject performed,
thereby preventing a calculation of SEM.  Superscript “x” indicates a group in which no
subjects performed.
Trials to Criterion
Male Female
Trial Type SAL DOM SAL DOM
Single Discrimination 6.33 ± 0.33 6.60 ± 0.60 7.25 ± 0.95 6.00y
Compound Discrimination 11.00 ± 3.21 9.80 ± 1.32 7.00 ± 0.71 8.00y
Intradimensional Shift 7.89 ± 0.93 6.00 ± 0.00* 7.75 ± 0.85 6.00y
Reversal 10.00 ± 0.91 10.75 ± 2.25 8.00 ± 0.48 6.00y
Extradimensional Shift 9.00 ± 0.71 12.20 ± 2.94 8.25 ± 1.44 
x
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Figure 2.  Mean ± SEM number of trials to criterion for DOM- and SAL-treated male
subjects to complete the IDS portion of the attentional set-shifting task.  The asterisk
indicates a statistically significant difference from controls (p # 0.05).
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Figure 3.  Mean ± SEM latency of DOM- and SAL-treated female subjects to enter the
goal box during T2 of the puzzle box procedure.  The asterisk indicates a statistically
significant difference from controls (p # 0.05).
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Figure 4.  Mean ± SEM latency of DOM- and SAL-treated female subjects to enter the
goal box during T3 of the puzzle box procedure.  The asterisk indicates a statistically
significant difference from controls (p # 0.05).
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Figure 5.  Mean ± SEM latency of DOM- and SAL-treated female subjects to enter the
goal box during T4 of the puzzle box procedure.  The asterisk indicates a statistically
significant difference from controls (p # 0.05).
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Figure 6.  Mean ± SEM latency of DOM- and SAL-treated female subjects to enter the
goal box during T10 of the puzzle box procedure.  The asterisk indicates a statistically
significant difference from controls (p # 0.05).
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more quickly than SAL-treated female counterparts.  No other statistically significant
effects were observed in the puzzle box paradigm.  See Table 5 for mean and SEM values
for the puzzle box paradigm. 
2.4  Discussion
The current study revealed minimal statistically significant DOM-induced effects in terms
of trials to criterion for the attentional set-shifting paradigm, with the exception of the
finding that DOM-treated males completing the IDS task with fewer errors than SAL-
treated male counterparts.  
The IDS task is one of the more basic types of trials in the attentional set-shifting
paradigm as it merely involves applying a previously learned rule to a new set of
stimulus.  Therefore, deficits in more challenging tasks such as the REV and EDS task
are generally expected to be seen more than are deficits in the IDS task.  Also, while
studies of marmoset monkeys has shown that dorsolateral PFC damage affects EDS task
performance and orbitofrontal cortex damage affects REV task performance (Dias et al.,
1996; Dias et al., 1997), the neurobiology of the IDS is less studied thus far, thereby
preventing the extrapolation of the current result in the identification of cortical areas for
further analyses.  Thus, statistically significant effects on IDS performance are
infrequently the target of the attentional set-shifting paradigm and are more poorly
understood, in terms of neurobiology, as compared to the REV and EDS tasks.  For
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Table 5.  Mean ± SEM latency to enter the goal box in subjects treated neonatally with
DOM and SAL.  Asterisk indicates a statistically significant difference between treatment
groups (p # 0.05).
Male Female
Trial SAL DOM SAL DOM
1 18.20 ± 3.43 20.80 ± 4.67 23.70 ± 6.21 20.40 ± 4.87
2 7.33 ± 2.94 10.70 ± 3.30 9.00 ± 2.45 2.11 ± 0.48*
3 9.11 ± 2.87 15.56 ± 9.12 14.30 ± 5.94 2.67 ± 0.62*
4 18.50 ± 6.04 38.00 ± 16.30 28.40 ± 6.91 8.50 ± 3.39*
5 8.30 ± 2.97 7.50 ± 1.93 10.50 ± 2.13 6.90 ± 1.65
6 22.60 ± 5.11 61.30 ± 16.26 61.00 ± 22.38 30.14 ± 4.51
7 29.14 ± 17.29 18.20 ± 4.56 26.13 ± 10.43 14.75 ± 6.68
8 29.78 ± 12.37 16.90 ± 8.38 19.86 ± 4.60 20.30 ± 7.84 
9 17.67 ± 5.52 25.00 ± 14.61 29.25 ± 12.15 7.80 ± 1.57
10 17.78 ± 4.47 20.90 ± 4.18 38.20 ± 10.13 17.00 ± 4.00*
11 21.44 ± 9.40 25.80 ± 5.42 22.70 ± 6.03 23.20 ± 10.00
12 18.13 ± 11.46 24.00 ± 8.28 43.89 ± 12.82 54.10 ± 14.99
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these reasons, the current finding of improved performance of the IDS task among DOM-
treated male rats may be a spurious result.  However, previous studies of the model have
reported heightened exploratory behaviour in simple tasks, especially in male subjects
(Gallant, 2009).  Thus, enhanced digging in the IDS appears consistent with this finding
as increased exploration may facilitate faster and more consistent responding. 
The relative lack of statistically significant effects may be due to the low subject
participation that was observed, as only 19 of the 39 subjects participated to some degree
(see Table 6).  However, this observation leads to some interesting findings related to
treatment-based and sex-based differences in participation.  One of these interesting
findings was that 14 of 20 males participated to some degree while only 5 of 19 females
participated to some degree.  This observation also lead to further analysis using a chi-
square analysis, which revealed that there was a statistically significant difference
between males and females, when collapsed for treatment, in terms of participation, with
male rats participating more often than females [÷ (1, N = 39)  = 7.74, p < 0.01]. 2  While
this, combined with the observation that many studies use only male subjects (Fox et al.,
2003; Barense et al., 2004; Cain et al., 2011), may indicate an innate difference between
sexes in predisposition to perform the digging task, other studies have successfully
included female rats (Lovic and Fleming, 2004; McLean et al., 2008).  Thus, it does not
appear as though an innate difference exists between males and females in ability or
likelihood to participate in the digging task.
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Table 6.  Number of subjects participating in the digging task.
Male Female
Trial Type SAL DOM SAL DOM
SD 9 5 4 1
CD 9 5 4 1
IDS 9 4 4 1
REV 8 4 4 1
EDS 8 4 4 0
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Another interesting finding was that, while trials to criterion did not reveal any significant
differences between DOM and SAL animals, 13 SAL-treated rats participated, at least to
some degree, in the experiment while only 6 DOM subjects participated to some degree. 
Based on the previous chi-square finding, which indicated that there was a sex effect in
terms of response likelihood with females having a very low response rate, attention was
directed solely at male data.  In terms of male data, 5 of 10 DOM-treated subjects
participated to some degree while 9 of 10 SAL-treated subjects participated to some
degree.  This observation also lead to further analysis using a chi-square analysis of the
likelihood of male subjects of each treatment condition to participate in the digging task. 
This analysis revealed that while a higher proportion of SAL-treated males participated to
some degree, there was no statistically significant treatment effect in the male groups,
although the statistical value approached significance [÷ (1, N = 39)  = 3.807, p = 0.051].2
Almost all of the subjects who did not participate in the digging task failed to dig even a
single time in the experimental chamber, an observation that informs possible
explanations for the low DOM group participation.  One possible explanation is that
increased sensitivity to novelty in the DOM-treated group could have contributed to their
generalized exploratory behaviour and a lack of specific digging behaviour.  This is
supported by previous studies that have shown by changing a single element in the
environment of DOM-treated male animals, they respond by treating the entire
environment as if it was novel and, in turn, engage in generalized exploratory behaviour
(Burt et al., 2008).  Thus, by replacing the cups between trials, introducing a new digging
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M and O, and experiencing lingering O from previous trials may have abolished any
habituation to the chamber and reduced the amount of specific digging behaviour. 
Another possibility is that differences in stress levels between treatment groups
contributed to low performance levels.  It has previously been shown that in high-stress
environments, such as the Morris water maze, DOM-treated subjects display novelty-
induced seizure-like behaviour (Doucette et al., 2004).  While it seems unlikely that the
current study produced an equivalent level of anxiety as the Morris water maze, which is
further supported by the lack of observable seizure-like behaviours, the act of an
experimenter being positioned above a rat and repeatedly reaching into the maze may
have evoked more stress than expected.  Alternatively, it has been suggested that DOM-
treated subjects demonstrate less stress and fear responses in environments such as the
elevated plus maze which are less stressful than the Morris water maze (Doucette et al.,
2007).  Perhaps low levels of stress in a fairly bland testing chamber resulted in subjects
becoming under-stimulated and losing interest in the testing chamber and its contents. 
This certainly seems possible based on the observation that the majority of the subjects
who did not participate in the study merely sat in a single position until being removed
from the maze.
However, despite the findings of sex-based and treatment-based differences in likelihood
to participate in the study, the fact remains that a lower number of subjects than expected
participated in the digging task.  Aside from the previously mentioned explanations for
low sex-specific and treatment-specific responding, potential explanations for the low
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success rate in general include (i) inadequate training, (ii) inadequate food restriction, (iii)
low motivation due to insufficient rewards for performance, (iv) intrinsic flaws, and/or
(v) external effects.  
Inadequate training does not seem likely based on the observation that when subjects
were pre-exposed to buried Sugar Crisp rewards in their home-cage, digging behaviour
was observed to occur almost immediately upon exposure to digging bowls.  However,
there was no pre-exposure to the O stimuli that were used, allowing for the possibility
that inadequate training was, in fact, a contributing factor to poor performance.  This also
seems unlikely since subjects who did not participate in digging did not seem to dig a
number of times and then, based on poor performance, grow frustrated and cease
responding.  Instead, the subjects that did not participate in digging almost universally did
not dig a single time, thus suggesting that inadequate training with the O stimulus was not
responsible for poor performance. 
Additionally, inadequate food restriction does not seem likely to explain the poor
performance.  Although rat weight was not assessed daily, the 15 g and 12 g of rat pellets
that were given to male and female subjects, respectively, for a period of at least 7 days
was in line with the procedures set out by Lapiz et al. (2006).  Also, both male and female
subjects lost an average of 12% of their original body weight by the end of the
experiment, which is in keeping with moderate food restriction.
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The possibility that low motivation was responsible for low performance also seems
unlikely.  This is due to the observation that, on the final day of testing, all subjects were
given, in their home cage, a bowl of 30 Sugar Crisp pieces, all of which were consumed
by each subject within 3 minutes.  However, these 30 pieces of Sugar Crisp were
obtainable with minimal effort, so it remains possible that the effort required to learn the
rules of the digging task and the effort of digging may have been greater than the reward
of the Sugar Crisp.  Also, the sheer number of rewards that could have been received
during a testing session seems enough to abolish any motivation.  However, this problem,
which would only have applied to rats who progressed far in the series of trials and,
therefore, received many rewards, was not apparent.
Intrinsic flaws in the experiment may have also negatively impacted the study.  These
include the O and digging M used, and the bowls used.  For example, in the current study
the scents were sprayed directly onto the digging M while, in previous studies, scents
were administered to the rim of the bowl, which was made of absorbent terracotta (Fox et
al., 2003).  It is possible that the mixing of the O into the digging M, where the food
reward was placed, resulted in a change in the flavour of the Sugar Crisp reward. 
However, again, the observation that the majority of the rats who did not participate in the
digging task never dug a single time reduces the likelihood of this possibility. 
Alternatively, it is possible that the choice of digging M negatively impacted the study. 
For example, some of the digging materials (i.e. paper and sponge) were often removed
from the digging cups, taken to a corner of the maze, and explored by subjects.  Perhaps
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choosing more small, fine digging M such as sand and gravel could have reduced this
behaviour. 
Finally, external effects may have negatively impacted the study.  These include
experimenter positioning, which involved sitting immediately behind the digging bowls,
and experimenter action, which involved re-filling bowls between trials and reaching into
the maze to replace bowls while the subject remained in the maze.  It certainly seems
possible that these behaviours served to increase the stress of the subjects and may have
reduced the likelihood of their responding, despite the fact that they had one hour of pre-
exposure to this type of experimenter behaviour during a habituation trial the day prior to
testing.  This is supported by a recent study which has shown both behavioural and
neurochemical signs of an increased stress-response, as evidenced by increased closed-
arm entries in the elevated plus-maze in DOM-treated subjects, increased expression of
á2a adrenergic receptors, á2c adrenergic receptors, and mineralocorticoid receptors in the
hippocampus of DOM-treated males, and a decreased ratio of glucocorticoid to
mineralocorticoid receptors in the hippocampus of DOM-treated males (Gill et al., 2012). 
Regardless, the experimental design could be altered to allow for the digging bowls to be
moved to and from the maze through an opening in the base of a wall, thereby reducing
the need for the experimenter to reach into the maze.  This would also allow a cover the
be placed on the top of the maze to reduce the visibility of the experimenter.  While these
alterations do not appear to be used in the procedures outlined in the literature (Fox et al.,
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2003; Barense et al., 2004; Cain et al., 2011), they may be helpful in reducing animal
stress and improving performance.
In terms of alterations that could be made to improve the current study, aside from the
previously mentioned alterations in maze structure and experimenter behaviour, there are
also variations of the current digging paradigm which may be more effective.  One of
these variations has been described by Stefani et al., (2003) and involves the use of an
elevated plus maze which has two arms, one of which is baited, which differ along the
dimensions of brightness and texture.  The same sequence of SD, CD, IDS, REV, and
EDS trials as was used in the current study is employed in this variation, and the number
of trials to reach a criterion level of correct responses is assessed.  Advantages of this
variation include the replacement of the O and M stimuli that were used in the current
study with brightness and texture stimuli may be beneficial as O intensity of the two
stimuli is different to match equally and any O from previous trials are likely to linger and
potentially lead to confounding stimuli effects.  Additionally, our laboratory has
previously employed elevated plus maze paradigms to assess emotionality (Doucette et
al., 2007), thereby supporting the assertion that DOM-treated animals are likely to
participate in a procedure that involves an elevated plus maze. 
The puzzle box paradigm revealed female-specific statistically significant differences in
terms of latency to enter the goal box T2 and T4, which assess short-term memory, and
for T3 and T10, which assess problem solving ability, with DOM-treated females
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completing the above-mentioned trials more quickly than SAL-treated counterparts. 
These results are in agreement with previous studies in the laboratory which showed that
animals treated neonatally with DOM show working memory deficits in the radial arm
maze (McQuaid, 2009), both working and long-term memory deficits in temporal
memory ability (Robbins, 2010) and abnormalities in other behaviours involving the
mPFC such as PPI (Adams et al., 2008) and latent inhibition (Adams, 2009). 
Additionally, abnormalities in puzzle box performance have been demonstrated in
various mice models of schizophrenia including those with mPFC lesions or hippocampal
lesions, those treated sub-chronically with dizocilpine, those constitutively lacking the
Glu1 subunit of AMPARs, and those over-expression D2 receptors in the striatum
(Abdallah et al., 2011). 
However, closer assessment reveals that, of the trials showing a statistically significant
treatment effect, T2, T3, and T4 all involved either a small or a large open door through
which subjects entered the goal box.  Thus, the task was of minimal difficulty and
perhaps required very little cognitive ability in terms of working memory capacity.  A
potential explanation for this observation is that the current study may involve
confounding effects of treatment and stress level.  Since the stress of being placed in a
large, bright, uncovered chamber served as the motivation for animals to enter the dark
chamber, differences in stress levels between groups may have interacted with and
masked any short-term memory, long-term memory, or problem solving abnormalities. 
Thus, the shorter latency to enter the goal box that was observed among DOM-treated
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females may have been due to an exaggerated stress-response to the aversive bright lights. 
This, again, is supported by recent studies of behavioural signs of the stress response and
neurochemical markers of the stress system which have suggested an exaggerated stress-
response in DOM-treated subjects (Gill et al., 2012).  The relative role of stress in the
current study could be assessed in the future by modifying the procedure to replace the
aversive bright light stimulus for promoting entry into the goal box with a more appetitive
stimulus, such as a food reward.  An alternative explanation is that while these tasks
required working memory ability, the cognitive load, in terms of the amount of
information that guided behaviour, was minimal compared to other studies of working
memory such as the radial arm maze.  Thus, the current lack of working memory
impairment may be due to the nature of the task as the vast majority of working memory
tasks that have demonstrated impairments in animal models and in the clinical population
involve a larger cognitive load (Holzman and Park, 1992; Goldberg et al., 1997; Enomoto
et al., 2008).
In summary, statistically significant effects were observed in both of the employed
paradigms, with DOM-treated males completing the IDS task with fewer errors than their
SAL-treated male counterparts.  Additionally, differences were seen in the puzzle box
during trials assessing short-term memory and problem solving ability, as evidenced
through DOM-treated females completing T2, T3, T4, T10 more quickly than SAL-
treated females. 
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Chapter 3 
Alterations in dopaminergic markers in rats treated neonatally with domoic acid
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Summary
The dopaminergic system has long been implicated in the pathophysiology of
schizophrenia.  Links between DA and schizophrenia were first established by the finding
that chlorpromazine, a DA antagonist used for its anxiolytic properties, is effective in
treating the positive symptoms of schizophrenia (as reviewed in Ban, 2007), and that DA
agonists such as amphetamine and cocaine are effective in producing positive symptoms
of schizophrenia (Serper et al., 1999; Ban, 2007).  These findings contributed to the
current understanding of the DA contribution to schizophrenia, which suggests that
prefrontal DA hypoactivity, mainly at D1 receptors, contributes to negative and cognitive
symptomatology while mesolimbic DA hyperactivity, mainly at D2 receptors, contributes
to positive symptomatology (as reviewed in Howes and Kapur, 2009).  Thus, the current
study was conducted in order to determine the effects of neonatal treatment with DOM on
the integrity of the DA system in adults animals, as evidenced through potential
alterations in D1 receptor, D2 receptor, and DAT in the mPFC.  Results using cell
counting methods revealed a statistically significant increase in DAT staining in the right
PRL of DOM-treated females.  No other significant differences were observed between
DOM-treated and SAL-treated animals in terms of D1, D2, or DAT staining in the PRL
or ILC.
3.1  Introduction
Dopamine is a catecholamine neurotransmitter that is important is various processes
including cognition (as reviewed in Nieoullon, 2002), motivation (as reviewed in Wise,
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2004), reward (as reviewed in Ikemoto, 2007), and motor functioning (Brück et al.,
2001).  Dopaminergic abnormalities have been implicated in various disorders including
Parkinson’s disease (Leenders et al., 1986; Frost et al., 1993), attention-deficit
hyperactivity disorder (LaHoste et al., 1996; Dougherty et al., 1999), and schizophrenia
(Seeman et al., 1993; Laruelle et al., 1996; Lieberman, 2004).  The association between
aberrant dopaminergic systems and schizophrenia has been investigated extensively,
leading to both the DA hypothesis of schizophrenia and to the development of various
treatment regimes, including antipsychotic drugs, which modulate the DA system (Kapur
et al., 2000; Potkin et al., 2003).
While there are four main dopaminergic pathways, the mesolimbic pathway, which
projects from the VTA to the limbic system (e.g. hippocampus, amygdala, NAcc, etc.)
and mesocortical pathway, which projects from the VTA to the cerebral cortex, are most
commonly implicated in schizophrenia.  The mesolimbic system functions in motivation
and reward-based behaviour (Wightman and Robinson, 2002) and increased activity is
associated with positive symptomatology while the mesocortical pathway involves higher
cognitive functions (Moghaddam et al., 1997) and hypoactivity is associated with
negative and cognitive symptoms.  
The mesolimbic and mesocortical DA pathways also differ from one another in terms of
postsynaptic receptor distribution with D1-like receptors (e.g. D1 and D5 receptors)
predominating in the mesocortical pathway and D2-like receptors (e.g. D2, D3, and D4
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receptors) predominating in the mesolimbic pathway (as reviewed in Howes and Kapur,
2009).  However, while there is variability between pathways in terms of postsynaptic
receptors, the D2 receptor serves as an autoreceptor to regulate presynaptic DA release in
both pathways (Gainetdinov et al., 1994).
Following the release of DA from mesocortical dopaminergic neurons and the subsequent
action of DA on postsynaptic and presynaptic receptors, DA is removed from the synaptic
cleft primarily through reuptake via DAT and NET but also, to a lesser degree, through
enzymatic degradation via COMT and MAO (as reviewed in Feldman, 1997).
Thus, D1 receptors, D2 receptors, and DAT are key components of the DA system and
immunohistochemical analyses of these markers can provide information on the structural
integrity of the system, and various abnormalities in these markers have been observed in
the clinical population.  These findings include the effectiveness of first-line atypical
antipsychotics, which act as D2 antagonists (Horacek et al., 2006).  However,
complications arise as the mechanism of action of these drugs remains somewhat unclear,
with the relative roles of both presynaptic and postsynaptic D2 antagonism, serotonin
receptor antagonism, and various combinations of receptor antagonism being the subject
of some debate.  Also, there is some degree of variability between atypical antipsychotics
in terms of receptor affinity (Horacek et al., 2006).  However, a more clear picture is
offered by more recent findings of decreased cognitive symptoms in animals treated with
SKF-38,393, a selective D1-like receptor partial agonist (McLean et al., 2009; Barnes et
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al., 2012) and decreased  positive and negative symptoms in animals treated with
JNJ-37822681, a selective D2 receptor antagonist (Schmidt et al., 2012).  Additional
findings of dopaminergic receptor abnormalities in schizophrenia include increased
prefrontal D1 receptor availability in a cohort consisting of both drug-naive and treated
individuals (Abi-Dargham et al., 2002), decreased prefrontal D1 receptors via PET
imaging in drug-naive patients (Okubo et al., 1997), and increased prevalence of the
!141C D2 receptor allele in patients with schizophrenia (Arinami et al., 1997).  In terms
of DAT, treatment with modafinil, which functions through a mechanism that is not yet
completely understood, has been shown to inhibit DAT functioning (Zokowska et al.,
2009) and, also, to improve attentional set-shifting ability (Turner et al., 2004).  These
findings linking D1 receptors, D2 receptors, and DAT to the pathophysiology and
treatment of schizophrenia can thereby serve as a guide in the assessment of the structural
integrity of the dopaminergic system in the further characterization of the novel DOM-
induced animal model of schizophrenia.
The previous findings of altered tyrosine hydroxylase, the rate-limiting enzyme in DA
synthesis, in the mPFC of animals treated with DOM (Robbins, 2010) and findings
relating to D1 receptors, D2 receptors, and DAT in the clinical population, combined with
the association between dopaminergic hypoactivity in the mesocortical pathway and the
expression of cognitive symptoms, has served as the theoretical rationale for the
examination of D1 receptors, D2 receptors, and DAT in the mPFC in an attempt to
further characterize a novel animal model of schizophrenia.  Mechanistically, neonatal
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treatment with DOM may alter DA markers as a result of the modulatory role of KARs on
DA release causing compensatory alterations in the DA system.  Alternatively, KAR
activity could increase intracellular calcium either directly, through the action of KARs
that contain either GluR5 or GluR6 subunits that have not undergone post-transcriptional
RNA glutamine-to-arginine editing, or indirectly, through the secondary activation of
NMDARs which can flux calcium, thereby affecting gene transcription.
The current study was performed with the objective of characterizing possible alterations
in the DA system following neonatal exposure with DOM with the hypothesis that DOM-
treated animals would demonstrate alterations in the DA system as evidenced through
changes in D1 receptor, D2 receptor, and DAT.
3.2  Materials and methods
3.2.1  Experimental animals and injection procedure
Refer to section 2.2.1
3.2.2  Tissue collection and sectioning
Following behavioural testing, at approximately PND 196, subjects (n = 24; 6 of each sex
x treatment group) were deeply anesthetized with sodium pentobarbitol (s.c. injection),
transcardially perfused with 100 mL of phosphate buffered saline (PBS) and 100 mL of
4% paraformaldehyde in PBS, and brains were dissected from the skull and post-fixed for
24 hours in 4%  paraformaldehyde in PBS.  Tissue was then transferred to 0.08% sodium
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azide in PBS until sectioning.  Prior to sectioning on a vibratome, a small notch was
placed in the right hemisphere of each brain to allow the identification of each
hemisphere.  Coronal sections (50 µm) were then obtained from areas of the mPFC (4.7
to 1.7 mm relative to bregma) (Paxinos and Watson, 1998).  Tissue was sectioned in
groups of six sections with the first three being kept for DAT, D1, and D2
immunohistochemistry, respectively, and the next three being kept as control sections for
DAT, D1, and D2 immunohistochemistry.  Tissue was stored in 24-well plates containing
0.08% sodium azide in PBS until the implementation of immunohistochemical
procedures.
3.2.3  Immunohistochemical analyses
The immunohistochemical procedures used to assess DAT, D1, and D2 were adapted
from Sesack et al. (1998), Huang et al. (1992), and Yung et al. (1995), respectively, and
began with a series of rinses (3 x 5 min unless otherwise stated) in PBS followed by a 30
minute incubation in 1% hydrogen peroxide in PBS.  Sections were then re-rinsed in PBS
prior to being incubated for 30 minutes in 1% sodium borohydride in PBS.  Another
series of rinses in PBS was then conducted prior to a 30 minute incubation in blocking
solution (5% normal horse serum (NHS), 2% bovine serum albumin (BSA), 0.2% milk,
in Tris buffered saline (TBS)).  Following incubation, blocking solution was removed and
sections were treated with the primary antibody to either DAT, D1, or D2 (rabbit anti-
DAT, polyclonal; rabbit anti-D1R, polyclonal; rabbit anti-D2R, polyclonal) (Millipore,
Billerica MA, USA) at a working dilution of 1:1000 in PBS for approximately 60 hours at
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4E C.  Rinses (5 x 5 min) in TBS were then performed prior to incubation for 2 hours in
biotinylated goat anti-rabbit immunoglobulin G (IgG) (Vector Laboratories, Burlingame
CA, USA) in TBS at a dilution of 1:100.  Tissue was then rinsed in TBS followed by a 2
hour incubation period in avidin-biotin complex (Vector Laboratories, Burlingame CA,
USA), after which the final set of rinses in TBS was performed.  Sections were then
floated in PBS onto slides and the peroxidase reaction was developed using 0.2%
hydrogen peroxide in diaminobenzidine (DAB) for 6 minutes.  Following treatment with
DAB, sections were rinsed with approximately 2 mL of both PBS and distilled water and
were left to dry overnight.  The following day, sections were dehydrated by undergoing a
series of 3 minute rinses in 70% ethanol (EtOH), 95% EtOH, 100% EtOH, 100% EtOH,
xylene, and xylene again before a final 45 minute rinse in xylene.  Sections were then
cover-slipped using Permount.
3.2.4  Quantification of staining
Equivalent sections from separate subjects were identified using the appearance of the
forceps minor corpus callosum as a landmark to identify sections approximately
equivalent to a location 2.7 mm relative to bregma (Paxinos and Watson, 1998). 
Photographs (at 250 x magnification) of the mPFC were taken using a digital Cannon
Rebel EOS xSi camera (Canon Canada Inc., ON, Canada) mounted on a MEIJI trinocular
ML5000 series microscope (MEIJI Techno America, CA, USA).  Instances of
immunoreactivity were operationally defined as dark-brown or black punctated dots
which represented sites of DAT, D1, or D2 localization (see Figures 7-13). 
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Figure 7.  D1 immunopositive staining in the right ILC of representative male (A) SAL-
treated and (B) DOM-treated subjects.
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Figure 8.  D1 immunopositive staining in the right PRL of representative male (A) SAL-
treated and (B) DOM-treated subjects.
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Figure 9.  D2 immunopositive staining in the right ILC of representative male (A) SAL-
treated and (B) DOM-treated subjects.
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Figure 10.  D2 immunopositive staining in the right PRL of representative male (A) SAL-
treated and (B) DOM-treated subjects.
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Figure 11.  DAT immunopositive staining in the right ILC of representative male (A)
SAL-treated and (B) DOM-treated subjects.
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Figure 12.  DAT immunopositive staining in the right PRL of representative male (A)
SAL-treated and (B) DOM-treated subjects.
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Figure 13. DAT immunopositive staining in the right PRL of representative female (A)
SAL-treated and (B) DOM-treated subjects.
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Instances of immunoreactivity were counted in a standard counting square that was
positioned in layers I-VI of the prelimbic cortex (PRL) and infralimbic cortex (ILC) of the
mPFC.  The PRL of the mPFC was identified as located at the midline of the brain, exactly
equidistant from the most dorsal and ventral regions of each section.  The ILC of the
mPFC was identified as one-third of the distance from the most ventral region of the
section.  Hemispheres were photographed separately and two images were acquired for
each hemisphere in order to ensure that the 1 mm thickness of the cortex was visible.
3.2.5  Data analyses
Based on previous studies of the DOM model showing extensive sex-specific effects
(Doucette et al., 2007; Adams et al., 2008; Adams 2009b; Burt et al., 2008a; Robbins,
2010; Ryan et al., 2011) and hemisphere-specific effects (Adams, 2009a; Robbins, 2010;
Greenan, 2011), DA marker data was separated for sex, hemisphere, and region of the
mPFC and was analyzed using Student's t-tests (PASW Statistics 18).  A result of p # 0.05
indicated statistical significance.
3.3  Results
Results of Student's t-tests revealed a statistically significant treatment effect [t(10) =
2.277, p = 0.046] with DOM-treated females demonstrating increased DAT staining in the
right PRL (see Figure 14).  No other statistically significant effects were observed in terms
of DAT, D1, or D2 staining.  See Tables 7-9 for mean and SEM values for D1, D2, and
DAT staining.
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Figure 14.  Mean ± SEM cell count measurement of DAT staining in the right PRL or
DOM- and SAL-treated female subjects.  The asterisk indicates a statistically significant
difference from controls (p # 0.05).
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Table 7.  Mean ± SEM for D1 cell counts in the PRL and ILC of rats treated neonatally
with DOM and SAL.
Brain Area Male Female
SAL DOM SAL DOM
right PRL 155.67 ± 18.91 165.83 ± 24.63 178.00 ± 7.31 164.33 ± 14.82
left PRL 176.00 ± 24.15 167.83 ± 19.11 168.50 ± 11.74 165.83 ± 24.51
right ILC 184.83 ± 21.61 161.83 ± 37.264 191.33 ± 16.58 182.80 ± 25.78
left ILC 180.83 ± 26.97 188.33 ± 19.92 207.83 ± 16.54 193.17 ± 14.80
mPFC (PRL
and ILC)
873.33 ± 105.17 851.67 ± 103.73 914.17 ± 38.51 849.80 ± 69.70
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Table 8.  Mean ± SEM for D2 cell counts in the PRL and ILC of rats treated neonatally
with DOM and SAL.
Brain Area Male Female
SAL DOM SAL DOM
right PRL 50.17 ± 9.10 60.33 ± 10.33 54.33 ± 11.71 51.00 ± 3.27
left PRL 89.67 ± 55.81 78.50 ± 19.56 79.50 ± 39.37 108.50 ± 36.77
right ILC 49.83 ± 13.89 60.17 ± 15.09 73.33 ± 14.63 72.50 ± 6.78
left ILC 81.50 ± 34.02 78.83 ± 14.08 102.50 ± 43.17 122.83 ± 33.79
mPFC (PRL
and ILC)
271.17 ± 95.30 277.83 ± 33.57 309.67 ± 82.79 354.83 ± 71.31
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Table 9.  Mean ± SEM for DAT cell counts in the PRL and ILC of rats treated neonatally
with DOM and SAL.  Asterisk indicates a statistically significant difference between
treatment groups (p # 0.05).
Brain Area Male Female
SAL DOM SAL DOM
right PRL 56.67 ± 16.38 96.33 ± 20.33 51.67 ± 10.39 103.50 ± 20.25*
left PRL 127.00 ± 67.63 111.33 ± 35.03 122.17 ± 64.62 129.83 ± 23.47
right ILC 77.17 ± 15.80 124.83 ± 27.46 78.83 ± 17.32 107.80 ± 35.01
left ILC 133.33 ± 51.40 167.00 ± 30.95 158.33 ± 59.47 182.50 ± 35.83
mPFC
(PRL and
ILC)
394.17 ± 143.87 499.50 ± 70.42 411.00 ± 131.37 527.80 ± 54.94
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However, a pattern was observed in terms of higher DAT in right and left PRL and ILC of
female and male DOM-treated rats as compared to SAL-treated counterparts, with the
exception of the left PRL.
3.4  Discussion
Results indicated that statistically significant differences between groups in terms of D1,
D2, or DAT staining the PRL, ILC, or when combined to give an mPFC value were
limited to an increase in DAT staining in the right PRL of female DOM-treated subjects.
Based on the hypodopaminergia in the mPFC, which is associated with negative and
cognitive symptoms in schizophrenia, an increase in DAT staining could be interpreted as
a contributing factor to such decreases in DA tone, as increased DAT could function to
remove DA from the synapse at an increased rate, thereby depleting synaptic DA levels. 
This is also supported by the observation that modafinil, which functions through
mechanism that is not yet completely understood, has been shown to inhibit DAT
functioning (Zokowska et al., 2009) and, also, to improve attentional set-shifting ability
(Turner et al., 2004).  The effectiveness of decreasing DAT activity in improving cognitive
symptomatology could support the proposition that increased DAT staining, which may
reflect increased DAT levels, functions to contribute to the variety of cognitive symptoms
that have been observed in the current study and in previous studies of the DOM model
(Burt et al., 2008a; Adams et al., 2009b; Robbins, 2010). Mechanistically, it is possible
that the observed increase in DAT staining is the result of a compensatory increase in DAT
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following neonatal overactivation of the mesocortical DA system.  It has been previously
noted that KARs serve to modulate the mesocortical DA system (Kalivas et al., 1988),
therefore stimulation of this pathway from PND 8-14 via DOM administration may have
served to promote an upregulation of DAT in order to remove excess DA from the
synapse, and this compensatory upregulation may have become imprinted, thereby
persisting into adulthood (Rice and Baroni, 2000).
Regardless, the current findings in terms of DA alterations in the mPFC are relatively
modest and are, in fact, surprisingly modest based on the variety of negative and cognitive
symptoms, which are believed to be associated with decreased prefrontal DA signalling,
that have been observed in the DOM model of schizophrenia.  These include spatial
memory abnormalities (McQuaid, 2009), social withdrawal (McInnis, 2009; Ryan et al.,
2009), and temporal memory dysfunction (Robbins, 2010).  Additionally, previous studies
have shown DA alterations in the prefrontal cortex of DOM-treated males, as evidenced
through decreased staining of tyrosine hydroxlase, the rate-limiting enzyme in DA
synthesis (Robbins, 2010).  Finally, more extensive statistically significant alterations were
expected based on previously mentioned studies of the clinical population which implicate
D1, D2, and DAT (Arinami et al., 1997; Okubo et al., 1997; Geddes, 2000; Abi-Dargham
et al., 2002; Kane et al., 2003; Turner et al., 2004; Floresco et al., 2005; Schmidt et al.,
2012).  However, despite the lack of extensive statistically significant results, the
information gained by the current study is important as it complements the previous
findings of altered tyrosine hydroxylase by further characterizing potential DA system
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alterations in the mPFC. 
While statistically significant treatment effects were limited to an increase in DAT staining
in the right PRL of female DOM-treated subjects, a consistent pattern was observed in
terms of higher DAT in right and left PRL and ILC of female and male DOM-treated rats
as compared to SAL-treated counterparts, with the exception of the left PRL.  It is possible
that immunohistochemical methods of analyses were sufficiently sensitive to detect trends
in staining, but insufficiently sensitive to completely detect statistically significant
alterations.  It is important to consider that while immunohistochemistry is a semi-
quantitative method that provides excellent information in terms of protein location, other
semi-quantitative methods, such as Western blots and high-performance liquid
chromatography, may provide better information in terms of protein content. 
Immunohistochemistry involves quantifying the number of immunoreactive areas in a
particular 50 micron section of tissue.  Thus, a very limited portion of the brain area of
interest is being assessed.  Also, Western blots and HPLC are also limited in their utility,
in part, since a significant increase in protein level provides no information on whether the
increase is due to a normal number of cells expressing an increased amount of the protein
and/or an increased number of cells expressing a normal level of the protein.  However,
simultaneous immunohistochemical and Western blot analyses could allow researchers to
assess the entire volume of a given brain area and also obtain information on the
anatomical location of protein levels.  Perhaps future studies in the laboratory will use
these complementary techniques in order to gain more information on given
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neurochemical markers.
Also, it is important to consider while there no were no statistically significant findings in
terms of D1 or D2 in the mPFC, the mPFC receives diverse innervation outside of DA,
and alterations in the noradrenaline, serotonin, acetylcholine, GABA, or other
neurotransmitter systems may underlie the behavioural findings that have been previously
described.  In fact, previous studies have shown abnormalities in the GABA system, as
evidenced through decreased glutamic acid decarboxylase 67 in the left CA3 of female
DOM-treated subjects (Adams, 2009).  Further examination of other neurotransmitter
systems associated with schizophrenia, in order to complement the findings related to the
DA system, are an important future direction for the DOM model. 
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Chapter 4
Alterations in caspase-3 in rats treated neonatally with domoic acid
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Summary
The symptomatology of schizophrenia involves a variety of symptoms such as altered PPI,
LI, hallucinations, and delusions, which have been speculated to share a common
underlying process related to an impaired ability to filter out irrelevant information (Braff
et al., 1977; Adler et al., 1982).  This suggests the possibility of a contribution by altered
synaptic connections, which could include decreased numbers of synapses resulting from
increased synaptic pruning, an increase in synaptic connections resulting in abnormal
connnectivity, or microscopic abnormalities in synaptic anatomy.  In fact, decreased
prefrontal white matter (Breier et al., 1992), increased prefrontal neuronal apoptosis
inhibitor protein (Vawter et al., 2002), abnormalities in prefrontal synaptic proteins such
as N-ethylmaleimide sensitive factor fusion protein and synapsin II (Mirnics et al., 2000),
and decreased prefrontal dendritic spine density (Garey et al., 1998) have been shown in
the clinical population, thereby supporting the concept of abnormal prefrontal synapse
anatomy and function.  The current study was conducted in order to determine the effects
of neonatal treatment with DOM on normal developmental apoptotic processes by
assessing caspase-3, an executioner caspase, in the prefrontal cortex of subjects at PND
21.  Results revealed a statistically significant decrease in optical density measurement in
the right PRL among DOM-treated males and a statistically significant decrease in cell
count measurements in the right PRL among DOM-treated females.   No other statistically
significant effects were observed in terms of caspase-3 staining.
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4.1  Introduction
Apoptosis is a form of programmed cellular death which, unlike necrosis, does not involve
the release of harmful substances into the extra-cellular environment (as reviewed in
Elmore, 2007).  There are three main pathways involved in apoptotic signalling: the
extrinsic pathway, the intrinsic pathway, and the perforin/granzyme pathway (as reviewed
in Elmore, 2007).  The extrinsic apoptotic pathway involves stimuli such as Fas ligand and
tumour necrosis factor á (TNF-á) stimulating death receptors which, in turn, are bound by
adapter proteins (as reviewed in Elmore, 2007).  These adapter proteins are then able to
associate with procaspase 8, leading to the formation of death-inducing signalling complex
and the auto-catalytic activation of procaspase 8, which converts inactive procaspase 3 to
caspase 3, marking the beginning of the execution pathway, which is the common end-
point of the intrinsic, extrinsic, and perform/granzyme pathway (as reviewed in Elmore,
2007).  The intrinsic apoptotic pathway involves stimuli such as excess intracellular
calcium ions, which can be due to excessive Glu stimulation, which opens mitochondrial
permeability transition  pores and leads to a loss of mitochondrial transmembrane potential
(as reviewed in Elmore, 2007).  Subsequently, cytochrome C is released from the
mitochondria, serving as a stimulus for the activation of apoptotic protease activating
factor-1 and procaspase 9, thereby forming an apoptosome which yields active caspase 9
(as reviewed in Elmore, 2007).  Finally, caspase 9 is able to convert inactive procaspase 3
to caspase 3, the common end-point of the intrinsic, extrinsic, and perforin/granzyme
pathway (as reviewed in Elmore, 2007).  The perforin/granzyme pathway involves
cytotoxic T cell-dependent release of perforin, granzyme A, and granzyme B (as reviewed
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in Elmore, 2007).  Perforin and granzyme A are able to activate DNAase, thereby
increasing DNA cleavage and cellular death while granzyme B is able to activate caspase
10 which, in turn, activates caspase 3 to stimulate the execution pathway (as reviewed in
Elmore, 2007).  The execution pathway, which begins with caspase 3 activation and be
triggered through the intrinsic, extrinsic, or perforin/granzyme pathways, involves various
mechanisms of cellular death including chromosomal degradation, cytoskeletal
degradation, and phagocytic uptake of apoptotic bodies (as reviewed in Elmore, 2007).
High levels of apoptosis occur during development as a consequence of an initial
overproduction of neurons.  It is estimated that up to half of the original neuronal
population is then pruned through apoptosis (Oppenheim, 1981; Burek and Oppenheim,
1999) with neurons which receive adequate stimulation through trophic support from glial
cells, presynaptic cells, and steroid hormones being retained and neurons not receiving
proper stimulation being pruned through apoptosis (Lindsay, 1979; Okada and
Oppenheim, 1984; Nordeen et al., 1985).  This process is critical and tightly regulated as
excessive levels can result in over-pruning of synaptic connections while insufficient
levels can result in under-pruning of synaptic connections, thereby leading to excessive
synaptic connections. 
Apoptosis has been linked with several neurodegenerative disorders such as Huntington’s
disease (Hickey and Chesselet, 2003), Alzheimer’s disease (Su et al., 1994), and
amyotrophic lateral sclerosis (Martin, 1999).  More recently, the role of apoptosis in
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schizophrenia has been investigated.  This is due to the subtle findings of reduced
neuropil, as evidenced through reduced number of dendritic spines and reduced total
dendritic length (Garey et al., 1998; Glantz and Lewis, 2000) and  reductions in
presynaptic markers such as synaptophysin and synaptosomal-associated protein 25
(Karson et al., 1999) in the cortex of those with schizophrenia.  Additionally, findings
include layer-specific reductions in interneurons in layer II of prefrontal cortex and in
layers II–VI of the anterior cingulate cortex (Benes et al., 1991) and  pyramidal neurons in
layer IV of anterior cingulate cortex (Benes et al., 2001), reductions in neuronal number in
the NAcc (Pakkenberg, 1990) and mediodorsal thalamus (Pakkenberg, 1987), and
reductions in oligodendrocytes and glial cells in general in the PFC (Cotter et al., 2002;
Hof et al., 2003) in those with schizophrenia.  These findings suggest either increased
cellular apoptosis or increased synaptic apoptosis, the latter referring to a form of
apoptosis that targets synapses and/or distal neurites without affecting the remaining
portion of a neuron (Mattson et al., 1998).  
Therefore, the current study was conducted in order to examine apoptotic processes in the
DOM animal model of schizophrenia with the hypothesis that DOM-treated animals
would demonstrate altered caspase-3 staining in the mPFC.
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4.2  Materials and methods
4.2.1  Experimental animals and injection procedure
Refer to section 2.2.1
4.2.2  Tissue collection and sectioning
At approximately PND 21 subjects (n = 20; 5 of each sex x treatment group) were deeply
anesthetized with sodium pentobarbitol (s.c. injection), decapitated, and brains were
dissected from the skull and stored in 4%  paraformaldehyde for 10 days.  Brains were
then transferred to 0.08% sodium azide in phosphate-buffered saline until sectioning. 
Prior to sectioning on a vibratome, a small notch was placed in the right hemisphere of
each brain to allow the identification of each hemisphere.  Coronal sections (50 µm) were
then produced in the area of the PRL (3.7 to 2.2 relative to bregma, respectively)
(Ramachandra and Subramanian, 2011).  In addition to every fourth section being kept for
caspase-3 immunohistochemistry, a control slice was kept for each brain.  Tissue was
stored 24-well plates containing 0.08% sodium azide in PBS until the implementation of
immunohistochemical procedures.
4.2.3  Immunohistochemical analyses
The immunohistochemical procedure used to assess active caspase-3, an executioner
caspase in cellular apoptosis, was adapted from a study by Lanshakov et al. (2009) and
began with a series of rinses (3 x 5 min unless otherwise stated) in PBS followed by a 30
minute incubation in 1% hydrogen peroxide in PBS.  Sections were then re-rinsed in PBS
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prior to being incubated for 30 minutes in 1% sodium borohydride in PBS.  Another series
of rinses in PBS was then conducted prior to a 30 minute incubation in blocking solution
(5% NHS, 2% BSA, 0.2% milk, 0.5% Triton X-100 in TBS).  Following incubation,
blocking solution was removed and sections were treated with the primary antibody to
active caspase-3 (rabbit anti-cleaved caspase-3; polyclonal) (Millipore, Billerica MA,
USA) at a working dilution of 1:1000 in PBS for approximately 60 hours at 4EC.  Rinses
(5 x 5 min) in TBS were then performed prior to incubation for 2 hours in biotinylated
goat anti-rabbit IgG (Vector Laboratories, Burlingame CA, USA) in TBS at a dilution of
1:100.  Tissue was then rinsed in TBS followed by a 2 hour incubation period in avidin-
biotin complex (Vector Laboratories, Burlingame CA, USA), after which the final set of
rinses in TBS was performed.  Sections were then floated in PBS onto slides and the
peroxidase reaction was developed using 0.2% hydrogen peroxide in DAB for 6 minutes. 
Following treatment with DAB, sections were rinsed with approximately 2 mL of both
PBS and distilled water and were left to dry overnight.  The following day, sections were
dehydrated by undergoing a series of 3 minute rinses in 70% EtOH, 95% EtOH, 100%
EtOH, 100% EtOH, xylene, and xylene again before a final 45 minute rinse in xylene. 
Permount was then administered and cover slips were placed on sections.
4.2.4  Quantification of staining
Equivalent sections from separate subjects were identified using the forceps minor of the
corpus callosum and lateral ventricle as landmarks.  The PRL of the mPFC was identified
as located at the midline of the brain, exactly equidistant from the most dorsal and ventral
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regions of each section.  Photographs (1000 x magnification) were taken of the left and
right hemispheres of representative sections of the PRL using a digital Cannon Rebel EOS
xSi camera (Canon Canada Inc., ON, Canada) mounted on a MEIJI trinocular ML5000
series microscope (MEIJI Techno America, CA, USA).  Instances of immunoreactivity in
the PRL, defined as dark, punctated somata which represent sites of caspase-3, were both
manually counted and digitally quantified using optical density measurements using
ImageJ software (1.41d, NIH, USA) (see Figure 15).  Optical density values were obtained
by mean staining intensity over each pixel in the areas of interest and subtracting the
minimum staining intensity, as a method of controlling for differences in background
staining, from the mean value.  
4.2.5  Data analyses
Based on previous studies of the DOM model showing extensive sex-specific effects
(Doucette et al., 2007; Adams et al., 2008; Adams 2009b; Burt et al., 2008a; Robbins,
2010; Ryan et al., 2011) and hemisphere-specific effects (Adams, 2009a; Robbins, 2010;
Greenan, 2011), caspase-3 data was separated for sex, hemisphere, and region of the
mPFC and was analyzed using Student's t-tests (PASW Statistics 18).  A result of p # 0.05
indicated statistical significance.
4.3  Results
Results of Student's t-tests revealed statistically significant treatment effects with DOM-
treated males demonstrating a decreased optical density measurement in the right PRL 
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Figure 15. Caspase-3 immunopositive staining in the right PRL of representative male (A)
SAL-treated and (B) DOM-treated subjects.
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[t(8) = -2.838, p = 0.022] (see Figure 16) and with DOM-treated females demonstrating a
decreased cell count measurement in the right PRL [t(8) = -2.307, p = 0.050] (see Figure
17).  See Table 10 for mean and SEM values for caspase-3 staining.
4.4  Discussion
The current study revealed that neonatal treatment with DOM from PND 8-14, a critical 
period of brain development which is approximately equivalent to the third trimester of 
human development, resulted in decreased caspase-3 staining in the right PRL of DOM-
treated males, as demonstrated by optical density measurements, and of DOM-treated 
females, as demonstrated by cell count measurements.  In addition to the statistically 
significant findings, there is a consistent trend of decreased caspase-3 staining, using both 
cell counting and optical density methods, in each hemisphere of the PRL in both genders.
The current findings of decreased caspase-3 in DOM-treated subjects are somewhat in
contrast to findings of unaltered levels of caspase-3 in the temporal cortex of post-mortem
human subjects (Jarskog et al., 2004) and unaltered levels of caspase-3 in organotypic
hippocampal slice cultures that were treated for 24 hours with concentrations up to 20 ìm
of DOM (Pérez-Gómez and Tasker, 2012).  
However, it is difficult to translate findings from post-mortem brains and in vitro
hippocampal brain slices to the mPFC of subjects at PND-21.  Alternatively, studies have
shown increased caspase-3 activity and caspase-3 positive cells in rat frontal cortex 
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Figure 16.  Mean ± SEM for the intensity of caspase-3 staining in the right PRL or DOM-
and SAL-treated male subjects.  Scores can range from 0 (lightest staining) to 1 (darkest
staining).  The asterisk indicates a statistically significant difference from controls (p #
0.05).
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Figure 17.  Mean ± SEM cell count measurement of caspase-3 staining in the right PRL or
DOM- and SAL-treated female subjects.  The asterisk indicates a statistically significant
difference from controls (p # 0.05).
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Table 10. Mean ± SEM for caspase-3 staining intensity, as quantified by optical density,
and cell counts in the PRL of rats treated neonatally with DOM and SAL.  Asterisk
indicates a statistically significant difference between treatment groups (p # 0.05).
Male Female
Measure SAL DOM SAL DOM
Right hemisphere cell
count
273.40 ±
21.81 
226.20 ±
24.46 
225.40 ±
17.084
176.00 ±
12.92*
Left hemisphere 
cell count
271.60 ±
34.25
227.80 ±
39.17
249.40 ±
19.40
205.00 ±
20.70
Right hemisphere optical
density
0.072 ±
0.003
0.050 ±
0.005*
0.080 ±
0.007
0.071 ±
0.012
Left hemisphere optical
density
0.060 ±
0.004
0.059 ±
0.006
0.081 ±
0.010
0.070 ±
0.007
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following treatment with atypical antipsychotics (Jarskog et al., 2007) and decreased Bcl-2
and an increased Bax/Bcl-2 ratio in the temporal cortex of those with schizophrenia
(Jarskog et al., 2004).  These findings, combined with the finding of unaltered caspase-3 in
the temporal cortex, may signify that while apoptosis is not increased in chronic
schizophrenia, the system is primed to over-respond to pro-apoptotic stimuli.
The observed decrease in staining through optical density measurements could have been
due to either less cells staining positive for caspase-3 or due to a similar number of cells
staining more weakly for caspase-3.  By combining optical density measurements with cell
counting methods,  which both show trends of decreased staining, it is made more likely
that the decreased caspase-3 staining was due to fewer cells staining positive for caspase-
3, since decreased cell counts were observed.  However, it remains possible, but less
likely, that the underlying abnormality was, in fact, that a similar number of cells were
merely staining more weakly for caspase-3.  This remains possible since some cells may
have become faint to the point of being non-detectable by visual cell counting methods.
Alternatively, it is possible that DOM treatment resulted in increased cell death at a point
prior to when animals were euthanized and brains were dissected for
immunohistochemical processing.  This allows for the possibility that a normal percentage
of the remaining cells in DOM-treated animals stained positive for caspase, but a lower
overall cell number resulted in the appearance that either less cells were staining positive
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for caspase-3 or the staining intensity was diminished.  This possibility could be examined
by euthanizing animals at various times throughout the PND 8-14 treatment period to
assess the progression of caspase-3 staining or by counter-staining serial sections with
cresyl violet stain to gain an appreciation for the total number of cells present.  Thus,
decreased caspase-3 staining could indicate lower levels of apoptosis, perhaps as a result
of low doses of DOM providing survival signals, or could be the result of an earlier period
of increased cell death.
Regardless, the staining intensity and cell counts for caspase-3 were lower in DOM-treated
animal, which is significant finding based on the importance of cell population size.  Cell
populations are controlled through the normal pruning of neurons and synapses which
occurs during development and is due in large part to inadequate survival signals.  These
survival signals can include nerve growth factor, BDNF, and Glu signalling (Bahr et al.,
2002; Davies, 2003).  Somewhat counter-intuitively, based on the role of Glu signalling in
excitotoxicity and cell death, Glu signalling at less than toxic doses is essential for
maintaining neuronal survival (McDonald and Johnston, 1990).  Thus, while an increase in
apoptotic markers may be expected following neonatal treatment with DOM, namely
through calcium-induced pathways leading to mitochondrial release of cytochrome C,
decreased caspase-3 staining could be due to increased pro-survival signalling.  This is
supported by both the fact that the current study involved only low doses of DOM
administration and the fact that there are no subsequent DOM-induced alterations in
developmental milestones as evidenced through eye opening, weight gain, and other
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measures (Doucette et al., 2003).
The finding of decreased prefrontal caspase-3 in DOM-treated subjects could also provide
insight into previously described behavioural abnormalities following neonatal treatment
with DOM.  As previously described, decreased caspase-3 staining could indicate lower
levels of apoptosis, perhaps as a result of low doses of DOM providing survival signals, or
could indicate an earlier period of increased cell death, perhaps as a result of Glu
hyperactivity.  Either of these scenarios would alter PFC structure and, in turn, function,
thereby potentially resulting in alterations in behaviours which depend on PFC circuitry
and which have been shown to be altered in the current model, include altered PPI (Adams
et al., 2008), abnormal LI (Adams, 2009), social withdrawal (McInnis et al., 2009; Ryan et
al., 2009), emotionality (Doucette et al., 2007), and temporal memory ability (Robbins,
2010). 
However, while there are obvious links to be made between abnormalities in behaviours
which are dependent on the prefrontal cortex, decreased prefrontal caspase-3, which is the
executioner caspase in apoptosis, and the potential for increased cellular survival in the
prefrontal cortex, the complexities of apoptosis must also be considered.  For example,
while the pro-apoptotic caspase-3 was decreased in DOM-treated subjects, the possibility
remains that there were reciprocal alterations in anti-apoptotic proteins such as Bcl-2, Bcl-
x, Bcl-xl, Bcl-xs, Bcl-w, or BAG, or potentially decreased levels of other pro-apoptotic
proteins such as other caspases, Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, or Blk (as reviewed
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in Jarskog et al., 2005).
An additional focus of future research could involve other proteins that have the potential
to be altered based on the possibility that DOM-induced calcium-influx may alter gene
expression.  It is interesting to note that increased intracellular calcium serves to activate
protein kinase C, thereby cleaving phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3
and DAG (as reviewed in Purves et al, 2008).  Subsequently, DAG triggers a signalling
pathway which includes Raf, MEK, ERK, fos, and finally AP-1, a transcription factor (as
reviewed in Purves et al, 2008).  Genes that are affected by AP-1 include tyrosine
hydroxylase (Gizand-Ginsberg and Ziff, 1990), DA â-hydroxylase (Nankova et al., 1994),
choline acetyltransferase (Hahn et al., 1992), among many others.  Assessment of DA â-
hydroxylase and choline acetyltransferase could serve as the next targets of investigation. 
Rationale for this choice includes not only clinical relevance, as DA â-hydroxylase
polymorphisms have been associated with symptom severity and response to treatment
(Yamamoto et al., 2003) and lower levels of choline acetyltransferase have in found in the
pontine tegmentum of subjects with schizophrenia (Karson et al., 1993), but also from
potential mechanistic connections between DOM treatment, previous laboratory findings,
calcium influx, and the AP-1 transcription factor.  First, neonatal exposure to DOM has
been previously shown to indirectly activate NMDARs, thereby potentially contributing to
calcium influx (Tasker et al., 2005).  Previous laboratory results have also shown altered
tyrosine hydroxylase staining in various brain areas including the PFC (Robbins, 2010). 
The transcription of the tyrosine hydroxylase gene is controlled, in part, by AP-1, a
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transcription factor that is inducible through a pathway that begins with increased
intracellular calcium levels (Gizand-Ginsberg and Ziff, 1990).  Therefore, it is possible
that neonatal treatment with DOM produces increases in intracellular calcium which
results in altered AP-1 and subsequent alterations in AP-1 targeted genes, such as tyrosine
hydroxylase, DA â-hydroxylase, and choline acetyltransferase.
Regardless, while the current findings suggest that further examination of the apoptotic
pathways is the DOM-model of schizophrenia is warranted, the current result is significant
not only in relation to previously reported cognitive abnormalities in DOM-treated
subjects but also in terms of providing further etiological validity for the model. 
Etiological validity involves recapitulating the clinical etiology of the disorder in question. 
As with the DISC-1 model, NMDAR antagonism models, and the neonatal VH lesion
model, the neonatal DOM-model has inherent etiological validity due to its
neurodevelopmental nature, and this validity is further strengthened through findings such
as altered caspase-3 in the PRL which suggests abnormal prefrontal connections.
In summary, altered caspase-3 in the PRL suggests abnormalities in synaptic structure and
function, a finding that is relevant in terms of improving the etiological validity of the
DOM-model of schizophrenia, providing a frame-work for understanding the cognitive
abnormalities that are observed in the neonatal DOM-model, and suggesting further
research in pro-apoptotic proteins, anti-apoptotic proteins, and proteins which under
transcriptional control of AP-1 (e.g. DA â-hydroxylase and choline acetyltransferase).
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Chapter 5 
General discussion
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The current study was conducted with the aim of further characterizing a novel animal
model of schizophrenia which involves neonatal exposure to DOM, a Glu agonist, during
a critical period of CNS development.  This was accomplished by assessing the face
validity, construct validity, and etiological validity of the model using the attentional-set
shifting and puzzle box paradigms, immunohistochemical analyses of D1, D2, and DAT,
and immunohistochemical analysis of caspase-3, respectively.
5.1  Face validity of low dose-domoic acid exposure as an animal model of
schizophrenia
Face validity, which refers to the phenomenological similarity in behavioural
abnormalities observed in the model and in the clinical population, is a key form a validity
for animal models of psychiatric disorders (Geyer and Markou, 2000).  Face validity, in
terms positive symptoms, negative symptoms, and cognitive symptoms, has been shown in
the current model (see Table 10).  The current study further characterized the face validity
of the model by assessing short-term memory, long-term memory, and problem solving
ability using the puzzle box paradigm, and by assessing attentional set-shifting ability
using the digging task.
Statistically significant results were obtained for both of the behavioural tests of cognition. 
These include improved cognitive flexibility on the IDS for DOM-treated males and
improved short-term memory and problem solving ability among DOM-treated females. 
While these results not only fail to demonstrate cognitive impairment in DOM-treated
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subjects, they actually show what appears to be cognitive improvement.  However, as
discussed previously, many of the statistically significant findings can be interpreted as the
result of an increased stress-response in DOM-treated subjects, a finding which has
previously been demonstrated (Gill et al., 2012).  Also, the working memory component of
the puzzle box task is much more simple than in previous studies (McQuaid, 2009).  Our
current understanding of the deficits in the cognitive domain in schizophrenia is currently
far from complete and the current findings may in fact provide insight into the
complexities of the cognitive alterations.  Whether the enhanced performance in the
working memory and problem-solving components of the puzzle box task is a byproduct
of increased stress, a faster (i.e. more impulsive) reaction time, or is in fact the result of
enhanced cognitive ability is intriguing.  Impulsivity is a key behavioural characteristic of
DA dysfunction and has been implicated in schizophrenia (Dursun et al., 2000; Hutton et
al., 2002) while at the same time a link between creativity and schizophrenia has been
proposed (de Manzano et al., 2010).  In either case, the findings highlight the fact that
impairments in one component of cognitive function does not necessitate generalized
deficits.  In addition to the potential influence of stress effects, differences in terms of
working memory demand, and impulsivity, the lack of cognitive impairments is not
entirely unexpected, stemming from the considerable symptomatic heterogeneity of
schizophrenia, which consists of residual, disorganized, catatonic, paranoid, and
undifferentiated subtypes, all of which involve subtle differences in symptoms expression
(DSM-IV-TR, 2000).  Since not all behavioural symptoms are manifested in each patient,
and the severity of symptoms also varies between patients, not all animal models are
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expected to exhibit all behavioural components of schizophrenia.  However, animal
models should ideally exhibit the  “gold-standard” behavioural of altered PPI, altered LI,
and social withdrawal, all of which have been exhibited in the DOM model (Adams et al.,
2009a; Ryan et al., 2011).  To this end, the face validity of the DOM model has already
been largely established (see Table 11), but it remains important to assess a wide-range of
behaviours that are associated with schizophrenia in order to more fully characterize the
persistent behavioural impacts of the proposed etiological insult.  
5.2  Construct validity of low dose-domoic acid exposure as an animal model 
of schizophrenia
Construct validity, which refers to the accuracy with which a test measures that which it is
intended to measure, is another key form a validity for animal models of psychiatric
disorders and is often established through analyses of underlying neurobiology (Geyer and
Markou, 2000).  Construct validity of the current model of schizophrenia has previously
been established through hippocampal findings including altered mossy fiber sprouting
and TrkB receptor expression (Bernard et al., 2007), altered BDNF and cell counts
(Doucette et al., 2004), altered GAD67 in the left CA3 region (Adams, 2009a), and
through mPFC findings including altered tyrosine hydroxylase staining (Robbins, 2010). 
The current study involved further characterizing the construct validity of the DOM model
by assessing DA markers such as D1, D2, and DAT in the mPFC in an attempt to establish
a mechanism for the manifestation of previous behavioural findings including altered PPI,
LI, and temporal memory ability.
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Table 11.  Summary of characteristics of schizophrenia which have been observed in the
current animal model of schizophrenia.
Type of Validity Displayed in Clinical Population Displayed in Model
Face
    Positive symptoms Drug and reward seeking Burt et al., 2008a
Psychomotor agitation Burt et al., 2008b
     Negative symptoms Emotional changes Doucette et al., 2007
Social withdrawal Ryan et al., 2011
     Cognitive symptoms Executive function deficits:
     Altered response to novelty Burt et al., 2008a
     Reversal learning Adams et al., 2009b
     Working memory Adams et al., 2009b
     Temporal memory dysfunction Robbins, 2010
Decreased PPI Adams et al., 2009a
Decreased LI Adams et al., 2009a
Construct 
 Hippocampal changes:
     Elevated BDNF Doucette et al., 2004
     Mossy fiber sprouting Bernard et al., 2007
     TrkB receptors Bernard et al., 2007
     Decreased GAD67 in left CA3 Adams et al., 2009a
Evidence of DA dysfunction Burt et al., 2008b,
Robbins 2010
Etiological
Acts on Glu system All references
Developmental in origin All references
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Again, statistically significant treatment effects were limited and manifested only as an
increase in DAT staining in the right PRL of DOM-treated females.  This finding was has
impact as increased DAT staining may indicate a net increase in DAT functioning which
could be the result of compensatory upregulation of DAT due to overstimulation of the
mesocortical DA system by DOM and could, in turn, contribute to the cognitive
abnormalities that have been previously demonstrated (Burt et al., 2008a; Adams et al.,
2009b; Robbins, 2010) by decreasing DA tone in the mPFC through increased synaptic
removal of neurotransmitter.
These relatively modest findings are, again, not completely unexpected since the strongest
studies linking the chosen markers to schizophrenia in the clinical population and other
animal models are limited to successful treatment with selective D1-like receptor partial
agonists (Abi-Dargham et al., 2002) and selective D2R antagonists (Schmidt et al., 2012), 
decreased prefrontal D1 receptors via PET imaging in drug-naive patients (Okubo et al.,
1997), and improvement of attentional set-shifting ability following treatment with
modafinil, which inhibits DAT functioning (Turner er al., 2004).  Regardless, the markers
were chosen based on the significant association between schizophrenia and altered
prefrontal DA signalling (Howes and Kapur, 2009) and the association between previous
behavioural findings (Doucette et al., 2004; Doucette et al., 2007; Burt et al., 2008a; Burt
et al., 2008b; Adams et al., 2009a; Adams et al., 2009a; Ryan et al., 2011) and findings of
DA alterations (Robbins, 2010) in the current model.  The construct validity of the current
model is not weakened by the lack of significant findings in terms of D1 and D2 receptors
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but, instead, these findings serve to guide further studies into the underlying
neurochemical alterations which are responsible for the behavioural abnormalities
manifested following neonatal DOM exposure.  The complex mPFC circuitry, which
involves many neurotransmitter systems including DA, Glu, GABA, serotonin,
noradrenaline, opiates, and neurotensin (as reviewed in Steketee, 2003), allows for many
potential avenues of future analyses, with previous studies of the clinical population and of
animal models indicating that the Glu (Dracheva et al., 2001), GABA (Beasley and
Reynolds, 1997), and serotonin (Hashimoto et al., 1991) systems are most strongly
implicated.
5.3  Etiological validity of low dose-domoic acid exposure as an animal model 
of schizophrenia
Etiological validity, which involves recapitulating the clinical etiology, is another key
form a validity for animal models of psychiatric disorders (Geyer and Markou, 2000). 
While etiological validity is not an essential component of all animal models, since
adequate face validity and predictive validity can allow for the effective assessment of
symptom manifestation and treatment, ensuring etiological validity can allow for the
confidence that behavioural symptoms are due to the same underlying process in the
model as they are in the clinical population.  However, etiological validity is often difficult
to establish since the etiology of the human condition is often poorly understood, as is the
case for schizophrenia.  In terms of current animal models of schizophrenia, inherent
etiological validity exists in the DISC-1 model, NMDAR antagonism models, and the
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neonatal VH lesion model.  However, the etiological validity of each of these models
appears limited as the DISC-1 model does not incorporate any non-genetic contributions to
schizophrenia, the NMDAR antagonism models involve relatively high-dose exposure to
NMDAR antagonists, and the neonatal VH lesion model involves an unrealistically severe
brain lesion.  While there is significant difficulty associated with establishing etiological
validity in a model of a disorder with an unknown etiology, it also allows for the
implementation of current understanding and knowledge of the etiology of schizophrenia
in an attempt to create a realistic model, as was done in the current and previous studies
employing neonatal exposure to DOM, a Glu agonist (see Table 10).  The current study
further characterized the etiological validity of the DOM model, which involves
developmental exposure to low-doses of a Glu agonist, by assessing immunohistochemical
staining of caspase-3, an executioner caspase involved in apoptosis, in the mPFC.  The
assessment of mPFC caspase-3 staining in DOM-treated subjects allowed for further
insight into previously described behavioural abnormalities following neonatal treatment
with DOM.  These include various behaviours which depend on prefrontal circuits,
include altered PPI (Adams et al., 2008), abnormal LI (Adams, 2009), social withdrawal
(McInnis et al., 2009; Ryan et al., 2009), emotionality (Doucette et al., 2007), and
temporal memory ability (Robbins, 2010). 
Results revealed a statistically significant decrease in optical density measurement in the
right PRL among DOM-treated males and a statistically significant decrease using cell
count measurement in the right PRL among DOM-treated females.   These findings could
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stem from an early upregulation of apoptotic pathways due to overactivity of KARs which,
in turn, could have reduced the available cell population, thereby producing low caspase-3
staining.  Alternatively, it is possible that the amount by which Glu tone was increased by
DOM administration was insufficient to activate apoptosis but instead served as a survival
signal to reduce the amount of apoptosis, thereby producing low caspase-3 staining.
In summary, the etiological validity of the DOM model is further strengthened by the
results of the caspase-3 analysis despite the unclear explanation for the findings, as they
indicate that DOM treatment is having a yet unclear effect on apoptosis, a key process in
brain maturation, which has relevance for a neurodevelopmental disorder such as
schizophrenia.
5.4  Future directions
The current thesis focussed on further establishing the face validity, construct validity, and
etiological validity of a novel animal model of schizophrenia, and future avenues of
investigation could involve focussing on any combination of these areas and, additionally,
could focus on establishing predictive validity. 
In terms of the three types of validity that were assessed in the current model, construct
validity may be the area which requires the most investigation in the future.  This stems
largely from the fact that a number of behavioural findings have been observed, but only
limited neurochemical studies have been conducted (see Table 11).  However, a difficulty
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arises in whether the targets of neurochemical studies should be markers that are related to
previously established behavioural abnormalities, or whether markers should be chosen
based on previous findings of alterations in the clinical population.  The choice between
these two alternatives is best taken upon considering the goals for the model and whether
they are more directed at generating novel findings that can guide clinical research, or
whether they are more directed at attempting to establish the degree to which the model
recreates each aspect of the clinical manifestation of schizophrenia.  An additional
difficulty with the former alternative is that there is no single marker that, alone, explains
complex behavioural findings, so the number of relevant neurochemical markers is vast,
making the firm establishment of construct validity a daunting task.  However, it seems as
though, at this point in the model, establishing potential links between neurochemical
markers and established behavioural abnormalities would provide a more clear, concise
picture than would examining disjointed systems in an attempt to replicate clinical
findings.  Based on the behavioural findings of social withdrawal (Ryan et al., 2011),
altered PPI and LI (Adams et al., 2009a), and temporal memory dysfunction (Robbins,
2010), which point to both mPFC and hippocampal abnormalities, various protein markers
of the Glu, GABA, and serotonin systems, such as synthetic enzymes, receptors,
transporters, and degradative enzymes, should be assessed in both of these brain structures.
Further studies on the face validity of the model could focus on the reassessment of
attentional set-shifting ability using the elevated plus maze procedure as previously
described (Stefani et al., 2003), as this could eliminate a number of the factors which are
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believed to have impaired subject performance in the current study.  However, an
alternative view is that since the major “gold-standard” behavioural alterations have been
observed in the model, spanning each of the major symptoms classes, perhaps the
previously established face validity should now be used in order to assess predictive
validity.  Predictive validity, which is considered by some to be the most important form
of validity, is often used to refer to the ability of a model to identify novel therapeutic
compounds (Geyer and Markou, 2000).  Therefore, an interesting future avenue for
research would involve assessing the ability of currently used atypical antipsychotics, such
as clozapine or risperidone, to reverse the previously observed findings of altered PPI,
altered LI, and social withdrawal.  Should these results reveal that atypical antipsychotics
are able to effectively treat subjects in the model, more novel treatment regimes could be
assessed.
Alternatively, while further assessments of construct validity and predictive validity are
both obvious future directions for research, one of the most unique features of the current
model is its strong etiological validity due to its neurodevelopmental nature and its
mechanistic links to abnormal Glu signalling during development, which is speculated to
contribute to schizophrenia (as reviewed in Goff and Coyle, 2001).  Many of the current
animal models of schizophrenia either have little etiological validity or, as previously
described, have inherent weaknesses in their etiological validity.  For this reason, further
examination of the etiological validity of the current model may be the most effective way
to further distinguish the DOM model providing unique information in terms of the
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etiology of schizophrenia.  Possible avenues of research include further assessment of
caspase-3 staining at various time-points with concurrent assessment of pro-apoptotic
proteins such as Bax and anti-apoptotic proteins such as Bcl-2 in the mPFC and
hippocampus, performing the terminal deoxynucleotidyl transferase-mediated
2´-deoxyuridine, 5´-triphosphate nick end-labeling method of assessing double-stranded
DNA breaks associated with apoptosis, and silver staining for cell death.
 
Prior to the decision of whether to further pursue studies on construct validity, face
validity, predictive validity, and/or etiological validity, it is important to carefully assess
the strengths of the current model, the strengths of the major currently accepted animal
models, and the goal for the current model in order to determine how to best proceed with
the current model in order to further our understanding of schizophrenia. 
5.5  Conclusion
The current study employed both behavioural analyses of mPFC functioning and
immunohistochemical analyses of mPFC cell death and DA system integrity in order to
further assess the face, construct, and etiological validity of the DOM model of
schizophrenia.
While only modest treatment effects were seen, the construct validity and etiological
validity of the model was nonetheless further strengthened.  Face validity was not
furthered by the current study, although treatment effects were observed, but this can be
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accounted for by the considerable behavioural and neurochemical heterogeneity the
clinical population.  Additionally, the model retains considerable face validity, construct
validity, and etiological validity based on previous behavioural studies, neurochemical
studies, and features of the developmental insult that is administered.  Future studies
should be conducted in order to further establish the neurochemical alterations that are
responsible for behavioural abnormalities in the model, to establish the predictive validity
of the model with the goal of making contributions to the development of novel treatment
regimes, and to further examine the mechanism whereby neonatal treatment with DOM
produces persistent behavioural and neurochemical alterations.
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